Document:

Exclusive Sublicense Agreement

 Exhibit 10.10 
 CONFIDENTIAL TREATMENT REQUESTED. 
 INFORMATION FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN 
 REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE 

CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS 

ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. 

EXCLUSIVE SUBLICENSE AGREEMENT 
 This Exclusive Sublicense Agreement (hereinafter referred to as this “Agreement”), effective as of this December 12, 2005 (the “Effective Date”), is entered into by and between
Ovamed GbmH & Co KG, a corporation duly incorporated under the laws of Germany and having a principal place of business at Kiebitzhörn 33-35, 22885 Barsbüttel, Germany (“Ovamed”) and Collingwood Pharmaceuticals, Inc., a
corporation duly organized and existing under the laws of the State of Delaware having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (the “Company”). 

WHEREAS, under the patent policy of The University of Iowa (“UI”), all inventions and technology arising during the
normal course of research and teaching at the UI are assigned and entrusted to the University of Iowa Research Foundation (“URIF”) to obtain patent or other appropriate intellectual property protection and license said technology;

 WHEREAS, UIRF is, therefore, owner by assignment from Joel Weinstock and David Elliott of their entire right, title
and interest in United States Patent 6,764,838 and United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249; Canada Patent Application Number 2,315,790; Japanese Patent Application Number 2000-526233; Australia Patent Number
740776, all titled “Use of Parasitic Biological Agents for Prevention and Control of Autoimmune Diseases”; 

WHEREAS, Ovamed has entered into an Exclusive License Agreement with URIF under which Ovamed has obtained an exclusive license to
the research, development and commercialization of intellectual property relating to the use of parasitic biological agents for the prevention and control of autoimmune diseases (the “Technology”) as claimed in the Patent Rights (as
defined below) in the Field (as defined below) in the Territory (as defined below) (the “License Agreement”); 

WHEREAS, the Company is interested in obtaining rights to the research, development and commercialization of intellectual property
relating to the Technology as claimed in the Patent Rights (as defined below) in the Field (as defined below) in the Territory (as defined below); 
 WHEREAS, Ovamed is willing to grant such rights to the Company so that the Technology may be developed and the benefits enjoyed by the public; 

 NOW, THEREFORE, it is agreed as follows: 

ARTICLE 1 – DEFINITIONS 
 For the purposes of this Agreement, the following words and phrases shall have the following meanings: 
 1.1 “Affiliate” shall mean, with respect to any Entity (as hereinafter defined), any Entity that directly or indirectly controls, is controlled by, or is under common Control with such
Entity. 
 1.1.1 “Control” shall mean, for this purpose, direct or indirect control of more than fifty percent
(50%) of the voting securities of an Entity or, if such Entity does not have outstanding voting securities, more than 50% of the directorships or similar positions with respect to such Entity. 

1.1.2 “Entity” shall mean any corporation, association, joint venture, partnership, trust, university, business, individual,
government or political subdivision thereof, including an agency, or any other organization that can exercise independent legal standing. 
 1.2 “Field” shall mean the prevention, treatment, cure or diagnosis of human diseases, with the exception of gastroenterology (e.g., inflammatory bowel disease) and hepatology in
Europe. 
 1.3 “Know-how” shall mean all tangible or intangible information (other than those contained in the
Patent Rights) whether patentable or not (but which have not been patented) and physical objects related to the Licensed Product, including but not limited to formulations, biological samples, tissues, animals, organisms, compounds, intermediates,
in vitro, preclinical or clinical design, other proprietary materials, processes, including but not limited to manufacturing processes, data, drawings and sketches and designs owned or controlled by Ovamed or which Ovamed has the right to disclose
and license to the Company. 
 1.4 “Licensed Product(s)” shall mean any product that cannot be manufactured,
used or sold, in whole or in part, without infringing one or more claims under Patent Rights in the country in which the product is made, used, leased, imported, offered for sale or sold. 

1.5 “Licensed Process(es)” shall mean processes which, in the course of being practiced would, in the absence of this
Agreement, infringe one or more claims of the Patent Rights. 
 1.6 “Net Sales” shall mean the total gross
receipts for sales of Licensed Products or practice of Licensed Processes by or on behalf of the Company or its Affiliates or Company Sublicensees (as applicable), whether invoiced or not, less only the sum of the following: (a) usual trade
discounts to customers; (b) sales, tariff duties and/or taxes directly imposed and with reference to particular sales; (c) amounts allowed or credited on returns or rejections; (d) bad debt deductions actually written off during the
accounting period; (e) outbound transportation prepaid or allowed and transportation insurance; (f) sales commissions; and (g) packaging and freight charges. 
 1.6.1 Notwithstanding anything to the contrary in this Article 1.6, Net Sales does not include sales of Licensed Product at or below the fully burdened cost of manufacturing solely for non-profit research
or clinical testing or for indigent or similar public support or compassionate use programs. If (i) the end user is a Company Sublicensee or an Affiliate or (ii) if Licensed Product or Licensed Process is sold for consideration other than
money, then Net Sales shall be calculated based on the final gross selling price of comparable Licensed Products sold in arm’s length transactions by Company to an end user. 

  
 2. 

 1.6.2 For purposes of determining Net Sales, Licensed Product shall be deemed to be sold
when shipped or to be the subject of a sale upon the delivery of Licensed Product to the purchaser or a common carrier at the risk of the purchaser and the transfer of title thereto to the purchaser. 

1.6.3 Sales between or among the Company, Company Sublicensee and their Affiliates shall be excluded from the computation of Net Sales
provided such parties are not the end-user of the products, but sales by such entities to their non-affiliated customers shall be included in such computation. 
 1.7 “Patent Rights” shall mean (a) United States Patent Number 6,764,838 and United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249; Canada Patent
Application Number 2,315,790; Japanese Patent Application Number 2000-526233; and Australia Patent Number 740776, all entitled “Use of Parasitic Biological Agents for Prevention and Control of Autoimmune Diseases”, patents issuing
thereon or reissues thereof; any and all foreign patents and patent applications corresponding thereto; any divisional, continuation in part, continuation and reexamination applications; and any extensions thereof; (b) any and all US or foreign
patents, patent applications, or other rights issuing from, or filed subsequent to the date of this Agreement, based on or claiming priority to or from the applications and rights listed in 1.1(a); and (c)any foreign counterpart to any of (a or b)
not otherwise listed therein. All such Patent Rights shall be set forth in Appendix A, attached to this Agreement and made part thereof. 
 1.8 Non-Royalty Sublicensing Income (“NRSI”) shall mean any and all consideration received from a Company Sublicensee in consideration for grant of a sublicense under the Patent Rights,
which shall include upfront and milestone payments, but expressly excludes all royalty payments; payments resulting from the sale of one or more Licensed Products; research and development funding; equity exchanges; and investment. 

1.9 Company Sublicensee means any other third party that has entered into a sublicense agreement with the Company to make, have
made, use, have used, lease, offer to sell, sell and/or have sold the Licensed Products and to practice and have practiced the Licensed Processes. 
 1.10 “Territory” shall mean the world, to the extent Ovamed possesses a license to practice the Patent Rights in specific countries and/or territories in the world. 

ARTICLE 2 – GRANT 
 2.1 Ovamed hereby grants to the Company and the Company accepts, subject to the terms and conditions of this Agreement, an exclusive license in the Field to practice under the Patent Rights and to
utilize the Know-how in the Territory, and (a) to make, have made, use, have used, lease, import, offer to sell, sell and/or have sold the Licensed Products and to practice and have practiced the Licensed Processes, to the full end of the term
for which the Patent Rights are granted, unless sooner terminated as hereinafter provided and (b) to sublicense to third parties, in accordance with Article 2.2 below, the rights granted under subsection (a) of this Article 2.1.

  
 3. 

 2.2 In accordance with 2.1 above, Ovamed hereby grants to the Company the right to
grant sublicenses to third parties under the license granted hereunder in the sole discretion of the Company. Upon termination of this Agreement other than by expiration in accordance with paragraph 9.9, any and all sublicenses shall survive such
termination, provided, however, Ovamed shall not be obligated to incur any obligation or duties to any former Company Sublicensee of the Company not already incurred or delegated to the Company by Ovamed in this Agreement. Notwithstanding the
foregoing, if Company believes that Ovamed has terminated this Agreement for the primary purpose of doing business directly with the Company Sublicensee, the termination may be disputed. 

2.3 Unless otherwise prohibited by law, Ovamed shall provide Company with and give Company access to the following:
(i) copies of all regulatory submissions, (ii) copies of all patient records, (iii) any communications and the minutes of any meetings with the FDA or other regulatory authority relating to the Licensed Product; (iv) trial master
files relating to any regulatory submission; (v) copies of all case report forms; (vi) all results of clinical trials conducted prior to and as of the Effective Date of this agreement relating to the Licensed Products, including without
limitation, clinical data, hard copy CRFs and reports; patient samples (such as blood samples, microbiology samples, and tissue samples) and access to ()yarned personnel with relevant expertise to explain the foregoing (vii) copies of all
computer data and reports pertaining to clinical trials, (viii) copies of all adverse event reports, (ix) copies of all preclinical evaluations, (x) any clinical trial material that has not expired, (xi) storage of and access
permission to biological samples, (xii) access to physicians, CROs and health care administrators involved in trials; (xiii) copies of an access to records and reports of any CMC related activities; (xiv) all drug manufacture files
along with the right to use manufacturing process and the manufacturing source, (xv) remaining quantities of any API (active pharmaceutical ingredient) and intermediates and (xvi) all other information that Company may reasonably request
regarding clinical trials and regulatory approvals. All costs related to the duplication of such materials will be borne by Company. In addition, Ovamed shall cross-reference or assign all regulatory filings, at Company’s option. From time to
time during the term of this Agreement, at the request of Company, Ovamed shall execute and deliver to Company such documents and take such other action as Company may reasonably request to consummate more effectively the transactions contemplated
hereby. Ovamed shall reasonably cooperate with Company and provide Company with such assistance as reasonably may be requested by Company, including with respect to the transfer of clinical data and filings with the FDA or other regulatory
authorities. 
 ARTICLE 3 – COMMERCIALIZATION 

3.1 The Company shall use all commercially reasonable efforts or shall cause its Affiliates or Company Sublicensees to use
commercially reasonable efforts, to bring a Licensed Product to market through a thorough, vigorous and diligent program for exploitation 

  
 4. 

 
of the Technology as timely and efficiently as possible. Such program shall include the preclinical and clinical development of Licensed Products, including research and development,
manufacturing, laboratory and clinical testing and marketing. The Company shall continue active, diligent marketing efforts for a Licensed Product throughout the term of this Agreement. 

3.2 Following the execution of this Agreement, Ovamed and the Company shall negotiate in good faith the terms of a Manufacturing
and Supply Agreement under which, subject to the terms of such agreement, Ovamed shall supply the Company with Licensed Product in amounts sufficient to satisfy the Company’s clinical and commercial requirements. 

ARTICLE 4 – ROYALTIES AND OTHER CONSIDERATION 
 4.1 Within ninety (90) days after the pre-IND meeting to be held at the United States Food and Drug Administration (“FDA”) on December 13, 2005 (“The pre-IND
Meeting”), the Company shall pay to Ovamed or directly to UIRF (at the Company’s option) the following: 
 4.1.1 a
non-refundable license fee of One Hundred Ten Thousand Dollars ($110,000) upon execution of this Agreement; 
 4.1.2 One Hundred
Percent (100%) of all monies paid by Ovamed to UIRF for costs incurred as of the effective date of the License Agreement relating to the preparation, filing, prosecution and maintenance of the Patent Rights where such costs as of July 20,
2005 were One Hundred Ninety Thousand Six Hundred Thirty Three Dollars and Ninety Three Cents ($190,633.93) plus any costs incurred by UIRF between July 20, 2005 and the Effective Date of this Agreement; 

4.2 The Company agrees to pay to Ovamed or directly to UIRF (at the Company’s option) the royalties set forth below, to the
end of the term of this License Agreement or until this Agreement shall be terminated as hereinafter provided. 
 4.1.1 During
the term of the License Agreement, the Company shall pay Ovamed or directly to UIRF (at the Company’s option) royalties equal to: four percent (4%) of Net Sales by the Company, Affiliates or Company Sublicensees; 

4.1.2 The Company shall also pay to Ovamed thirty percent (30%) of any NRSI received by the Company as a result of the sublicensing
of any of the Patent Rights prior to the pre-IND meeting in the United States or a foreign equivalent; twenty percent (20%) of NRSI subsequent to the pre-IND but prior to commencement of clinical trials; fifteen percent (15%) of NRSI after
commencement of clinical trials, but prior to the completion of enrollment of a phase II clinical trial; and ten percent (10%) of any NRSI subsequent to enrollment of a Phase II clinical trial. 

4.3 As further consideration for the license granted hereunder, the Company will make the following one-time milestone payments
(each a “Milestone Payment”) to Ovamed. 

  
 5. 

 4.3.1 One Million Five Hundred Thousand] Dollars ($1,500,000) upon acceptance by the FDA of
a Company-, Affiliate- or Company Sublicensee- sponsored Investigational New Drug Application (an “IND”) for a Licensed Product; 
 4.3.2 One Million Five Hundred Thousand Dollars ($1,500,000) upon the one year anniversary of the acceptance by the FDA of a Company-, Affiliate- or Company Sublicensee- sponsored IND for a Licensed
Product; 
 4.3.3 Two Hundred Thousand Dollars ($200,000) upon completion by the Company of the issuance of the Company’s
debt or equity securities to qualified investors in exchange for aggregate cash proceeds equal to or in excess of Five Million Dollars ($5,000,000); 
 4.3.4 Six Hundred Thousand Dollars ($600,000) upon the acceptance for review by the FDA of the first Company-, Affiliate- or Company Sublicensee- sponsored New Drug Application (“NDA”) for a
Licensed Product; 
 4.3.5 One Million Seven Hundred Fifty Thousand Dollars ($1,750,000) upon the final approval by the FDA of
the first Company-, Affiliate- or Company Sublicensee-sponsored NDA for a Licensed Product; 
 4.3.6 One Million Two Hundred
Fifty Thousand Dollars ($1,250,000) upon the final approval by the FDA of each subsequent Company-, Affiliate- or Company Sublicensee-sponsored NDA for a Licensed Product having an indication other than the indication on which the milestone of 4.3.5
is based; 
 4.3.7 Two Hundred Thousand Dollars ($200,000) upon the acceptance for review of the first Company-, Affiliate- or
Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in the European Union by the European Agency for Evaluation of Medicinal Products (the “EMEA”) or its successor organization; 

4.3.8 Four Hundred Thousand Dollars ($400,000) upon the final approval by the EMEA or its equivalent of the first Company-, Affiliate- or
Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in the European Union; 
 4.3.9 Four
Hundred Thousand Dollars ($400,000) upon the final approval by the EMEA or its equivalent for each subsequent Company-, Affiliate- or Company Sublicensee-sponsored application for the commercial sale of a Licensed Product having an indication other
than the indication on which the milestone of 4.3.8 is based; 
 4.3.10 Two Hundred Thousand Dollars ($200,000) upon the
acceptance for review of the first Company-, Affiliate- or Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in Japan by the Ministry of Health, Labor, and Welfare or its equivalent (“MHLW”);

 4.3.11 Four Hundred Thousand Dollars ($400,000) upon the final approval of a Company-, Affiliate- or Company Sublicensee-
sponsored application for the commercial sale of a Licensed Product in Japan by MHLW; 

  
 6. 

 4.3.12 Four Hundred Thousand Dollars ($400,000) upon the final approval of each subsequent
Company-, Affiliate- or Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in Japan by MHLW having an indication other than the indication on which the milestone of 4.3.11 is based; 

4.3.13 Two Hundred Thousand Dollars ($200,000) upon the acceptance for review of the first Company-, Affiliate- or Company Sublicensee-
sponsored application for the commercial sale of a Licensed Product in Canada by Health Canada or its equivalent; 
 4.3.14 Four
Hundred Thousand Dollars ($400,000) upon the final approval of a Company-, Affiliate- or Company Sublicensee- sponsored application for the commercial sale of a Licensed Product by Health Canada or its equivalent; 

4.3.15 Three Hundred Fifty Thousand Dollars ($350,000) upon the final approval of each subsequent Company-, Affiliate- or Company
Sublicensee- sponsored application for the commercial sale of a Licensed Product in Canada by Health Canada or its equivalent having an indication other than the indication on which the milestone of 4.3.14 is based; 

4.3.16 One Hundred Fifty Thousand Dollars ($150,000) upon acceptance for review of the first Company-, Affiliate- or Company Sublicensee-
sponsored application for the commercial sale of a Licensed Product in Australia by the Pharmaceutical Benefits Advisory Committee or its equivalent (“PBAC”); 
 4.3.17 Three Hundred Fifty Thousand Dollars ($350,000) upon final approval of a Company-, Affiliate- or Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in
Australia by the PBAC; and; 
 4.3.18 Three Hundred Fifty Thousand Dollars ($350,000) upon final approval of each subsequent
Company-, Affiliate- or Company Sublicensee- sponsored application for the commercial sale of a Licensed Product in Australia by the PBAC having an indication other than the indication on which the milestone of 4.3.17 is based. 

4.4 No multiple royalties shall be payable because the use, lease or sale of any Licensed Product or Licensed Process is, or shall
be, covered by more than one valid and unexpired claim contained in the Patent Rights. 
 4.5 In the event that a
Licensed Product or Licensed Process is sold in the form of a combination product/process containing one or more products or technologies which are themselves not a Licensed Product or Licensed Process, the Net Sales for such combination
product/process shall be calculated by multiplying the sales price of such combination product by the fraction A/(A+B) where A is the invoice price of the Licensed Product/Licensed Process or the Fair Market Value of the Licensed Product/Licensed
Process if sold to an Affiliate and B is the total invoice price of the other products or technologies or the Fair Market Value of the other products or technologies if purchased from an Affiliate. 

4.6 Royalty payments shall be paid in United States dollars at such place as Ovamed may reasonably designate consistent with the
laws and regulations controlling in the United States and if applicable in any foreign country. Any taxes which the Company, its Affiliate or 

  
 7. 

 
any Company Sublicensee shall be required by law to withhold on remittance of the royalty payments shall be deducted from such royalty payment to Ovamed. The Company shall furnish Ovamed with the
original copies of all official receipts for such taxes. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate prevailing at Citibank, N.A. in New
York, New York on the last business day of the calendar quarterly reporting period to which such royalty payments relate. 

4.7 Royalties payable to Ovamed shall be paid semi-annually on or before June 30 and December 31 of each calendar year.
Each such payment shall be for unpaid royalties which accrued within or prior to the Company’s two most recently completed fiscal quarters. 
 4.8 Commencing on the fourth anniversary of the execution date of this Agreement, the Company shall remit to Ovamed or to UIRF (at the Company’s option) an annual license maintenance fee
payment of Two Hundred Fifty Thousand Dollars ($250,000). Notwithstanding the limitations of this Article 4.8, annual license maintenance fees paid hereunder shall be reduced by the total amount of any milestones and royalties accrued to the
Company, an Affiliate or a Company Sublicensee solely during the relevant agreement year but shall not be reduced by (a) any royalties accruing in any other agreement year or (b) contract research funding payable to the University of Iowa
or UIRF pursuant to the terms of any research or development agreement. 
 4.9 No payment obligations shall be due with
respect to any sale or sublicense covering any Licensed Product in a country if there are no issued Patent Rights underlying such Licensed Product in such country. 
 4.10 To the extent that the Company, its Affiliate, or its Company Sublicensee is required (i) in its sole discretion after appropriate legal analysis, or (ii) by order or judgment of any
court in any jurisdiction, to obtain a license from a third party in order to practice the rights purported to be granted to the Company by Ovamed hereunder under Patent Rights in such jurisdiction, then up to [*******] percent
([*******]%) of the royalties payable under such license in such jurisdiction may be deducted from royalties otherwise payable to Ovamed hereunder, provided that in no event shall the aggregate royalties payable to Ovamed in any semi-annual
period in such jurisdiction be reduced by more than [*******] percent ([*******]%) as a result of any such deduction, provided further that any excess deduction remaining as a result of such limitation may be carried forward to
subsequent periods. 
 4.11 Should the Company fail to make any payments due to Ovamed pursuant to Articles 4.1, 4.2,
4.3, 4.8 and 6.1 of this Agreement, Paramount Biosciences, LLC (“Paramount”) shall make such payments to Ovamed on the Company’s behalf (such payments may be made directly to UIRF, at the Company’s option). In return for
such payments, Paramount will receive promissory notes from the Company in amounts equal to those amounts remitted by Paramount to Ovamed (or UIRF as applicable) pursuant to the preceding sentence (the “Notes”) that will accrue
interest at [*******] percent ([*******]%) per annum, compounded [*******], and [*******] percent ([*******]%) upon default. The Notes will become due and payable in [*******] months from the date of payment
by Paramount of the applicable fund to Ovamed (or UIRF as applicable). The Notes will also convert into shares of [*******], at Paramount’s option, at a per share price representing a [*******] Dollars

  
 8. 

 
($[*******]) valuation of the Company, should the Company fail to repay any outstanding Note when due. Paramount’s obligation to Ovamed and the Company under this Article 4.11 shall
terminate upon such time as the Company has received in excess of [*******] Dollars ($[*******]) in gross proceeds as a result of the sale of its equity securities. 

ARTICLE 5 – REPORTS AND RECORDS 
 5.1 The Company shall report to Ovamed the date of first sale of Licensed Products (or results of Licensed Processes) in each country within thirty (30) days of occurrence. 

5.2 The Company agrees to submit to Ovamed within [*******] days after the calendar quarters ending
March 31, June 30, September 30, and December 31, reports setting forth for the preceding three (3) month period at least the following information: 

(i) the number of the Licensed Products sold by the Company, its Affiliates and its Company Sublicensees in each country; 

(ii) total billings for such Licensed Products; 
 (iii) an accounting for all Licensed Processes used or sold; 
 (iv) deductions
applicable to determine the Net Sales thereof; 
 (v) the amount of royalty due thereon; 

and with each such royalty report to pay the amount of royalty due. Such report shall be certified as correct by an officer of the Company and shall
include a detailed listing of all deductions from royalties as specified herein. If no royalties are due to Ovamed for any reporting period, the written report shall so state. All such reports shall be maintained in confidence under Article 15 of
this Agreement. 
 ARTICLE 6 – FILING, PROSECUTION AND MAINTENANCE 

6.1 Pursuant to Article 4.1.2, the Company shall reimburse Ovamed or may reimburse UIRF directly (at the Company’s option)
for all reasonable expenses Ovamed has paid to UIRF under the License Agreement in connection with the preparation, filing, prosecution and maintenance of Patent Rights and the Company shall reimburse Ovamed for monies Ovamed has paid to UIRF under
the License Agreement for all such future expenses upon receipt of invoices from Ovamed and/or UIRF. It is understood that UIRF shall take responsibility for the preparation, filing, prosecution and maintenance of any and all patent applications and
patents included in Patent Rights. 
 6.2 Ovamed and the Company shall cooperate fully in the preparation, filing,
prosecution and maintenance of Patent Rights and of all patents and patent applications licensed to the Company hereunder, executing all papers and instruments or causing members of UIRF to execute such papers and instruments as to enable UIRF to
apply for, to prosecute and to maintain 

  
 9. 

 
patent applications and patents in UIRF’s name in any country. Each party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the
preparation, filing, prosecution or maintenance of any such patent applications or patents. 
 6.3 If the Company elects
to no longer pay the expenses of a patent application or patent included with Patent Rights, the Company shall notify Ovamed not less than sixty (60) days prior to such action and shall thereby surrender its rights and extinguish its
obligations under such patent or patent application. 
 6.4 Notwithstanding anything to the contrary herein, Ovamed
and/or UIRF will provide the Company with ample time in which to review and comment on any communication for which submission to any patent office is intended, including but not limited to responses to official actions, amendments, affidavits,
declarations and patent applications. In no event shall Ovamed provide the Company with less than seven (7) business days in which to review an intended patent office submission prior to such submission. Ovamed shall use best efforts, and shall
cause UIRF to use best efforts, to accommodate the Company’s requests to (a) enter and/or amend a claim in a pending patent application under the Patent Rights or (b) file additional patent applications as reasonably needed to advance
the purposes of this Agreement or to protect the rights and licenses granted hereunder. Ovamed further agrees to cause UIRF to retain patent counsel to prosecute and maintain the Patent Rights that is reasonably acceptable to the Company with
respect to quality of work and responsiveness. Within [*******] days of the Effective Date of this Agreement, Ovamed and the Company shall develop, in good faith, a budget for controlling all costs associated with the preparation, filing,
prosecution and maintenance of the Patent Rights. Ovamed and/or UIRF shall obtain the Company’s prior written consent for any such costs that exceed the budget by more than [*******] percent ([*******]%). 

6.5 Notwithstanding anything to the contrary herein, Ovamed shall cause UIRF to authorize UIRF’s patent counsel to
communicate directly with the Company on the same basis that said patent counsel communicates with UIRF with respect to the prosecution of Patent Rights.  
 ARTICLE 7 – MARKING 
 7.1 If a licensed patent has been
or is subsequently issued to UIRF covering any feature or features of the Licensed Products, the Company agrees to mark each and every package or container in which the Licensed Products are used or sold by or for the Company with marking complying
with the provisions of Title 35, U.S. Code, Section 287, if required, or any future equivalent provisions of the United States relating to the marking of patented devices, or with marking complying with the law of the country where the Licensed
Products are shipped, used or sold. 
 ARTICLE 8 – INFRINGEMENT 

8.1 The Parties shall promptly provide written notice to each other of any alleged infringement or any challenge or threatened
challenge to the validity, enforceability or priority of any of the Patent Rights, and provide each other with any available evidence of such infringement, challenge or threatened challenge by a third party of the Patent Rights and provide such
other party with any available evidence of such infringement. 

  
 10.

 8.2 During the term of this Agreement, the Company shall have the right, but not the
obligation, to institute such action as it deems appropriate at its own expense and utilizing counsel of its choice, to terminate the infringement of, and/or challenge to, the Patent Rights in the Territory in the Field through negotiation,
litigation and/or alternative dispute resolution means, provided that the Company shall not act in any arbitrary or capricious manner and shall not act in contravention or breach of the licenses granted to the Company hereunder. Ovamed shall
reasonably cooperate in any such action, and shall cause UIRF to reasonably cooperate in any such action in accordance with the terms of the License Agreement. Pursuant to the License Agreement, UIRF may join the Company as a party in any such suit
(and will join at Ovamed’s request), provided that the Company and/or Ovamed pay all of UIRF’s reasonable out-of-pocket expenses. Any recovery of damages pursuant to this Article 8.2 shall be retained entirely by the Company and allocated
pursuant to 8.4 below. 
 8.3 In the event that a claim or suit is asserted or brought against the Company alleging that
the manufacture or sale of any Licensed Product or Licensed Process by the Company, an Affiliate, or Company Sublicensee, or the use of such Licensed Product or Licensed Process by any customer of any of the foregoing, infringes proprietary rights
of a third party, the Company shall give written notice thereof to Ovamed. The Company may, in its sole discretion, modify such Licensed Product or such Licensed Process to avoid such infringement and/or may settle on terms that it deems advisable
in its sole discretion, subject to paragraph 8.2. Otherwise, the Company shall have the right, but not the obligation, to defend any such claim or suit. In the event the Company elects not to defend such suit, Ovamed shall have the right, but not
the obligation to do so at its sole expense. 
 8.4 Any recovery of damages by the Company, in any such suit under
Article 8.2 and 8.3, shall be applied first in satisfaction of any unreimbursed expenses and legal fees of the Company relating to the suit. The balance remaining from such suit shall be allocated accordingly: (a) amounts relating to lost sales
shall be allocated in their entirety to the Company, provided however, that Company shall pay Ovamed royalties due for such lost sales pursuant to Article 4 of this Agreement; and (b) any amounts remaining after the allocation of amounts
pursuant to 8.4(a) shall be divided equally between the Company and Ovamed. 
 8.5 The Company may credit the cost of any
litigation costs incurred by the Company in any country in the Territory pursuant to this Article 8 including all amounts paid in judgment or settlement of litigation within the scope of this Article 8 against royalties or other fees thereafter
payable to Ovamed hereunder for such country. If the costs of such litigation in such country exceeds the royalties payable to Ovamed in any year in which such costs are incurred then the amount of such costs, expenses and amounts paid in judgment
or settlement, in excess of the royalties payable shall be carried over and credited against royalty payments in future years for such country. 
 8.6 If within [*******] months after receiving notice of any alleged infringement of the Patent Rights, the Company shall have been unsuccessful in persuading the alleged infringer to desist, or
shall not have brought and shall not be diligently prosecuting an infringement action, or 

  
 11.

 
if the Company shall notify Ovamed, at any time prior thereto, of its intention not to bring suit against the alleged infringer, then, and in those events only, the Company shall have the right,
but not the obligation, to prosecute, at its own expense and utilizing counsel of its choice, any infringement of the Patent Rights, and the Company may, for such purposes, join Ovamed and/or IMF as a party plaintiff. The total cost of any such
infringement action commenced solely by Ovamed shall be borne by Ovamed and Ovamed shall keep any recovery or damages for infringement or otherwise derived therefrom and such shall not be applicable to any royalty obligation of the Company.

 8.7 In any suit to enforce and/or defend the Patent Rights pursuant to this Agreement, the party not in control of
such suit shall, at the request and expense of the controlling patty, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and
the like. 
 8.8 If the Company, its Affiliate or Company Sublicensee elects to commence an action as described above,
the Company may reduce, by up to [*******] percent ([*******]%), the royalty due to Ovamed earned under the patent subject to suit by [*******] percent ([*******]%) of the amount of the expenses and costs of such action, including attorney fees. In
the event that such [*******] percent ([*******]%) of such expenses and costs exceed the amount of royalties withheld by the Company for any calendar year, the Company may to that extent reduce the royalties due to Ovamed from the Company in
succeeding calendar years, but never by more than [*******] percent ([*******]%) of the royalty due in any one year. 

ARTICLE 9 – TERMINATION OF AGREEMENT 
 9.1 Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the Parties hereunder shall cease, except as follows: 

 

	(a)	Ovamed’s right to receive or recover and the Company’s obligation to pay royalties accrued or accruable for payment at the time of any termination;

  

	(b)	Ovamed’s obligation to maintain records and the Company’s right to conduct a final audit as provided in Article 5 of this Agreement; and

  

	(c)	Any cause of action or claim of by either party, accrued or to accrue because of any breach or default by the Company. 

9.2 In the event the Company fails to make payments due hereunder which is not subject to a bona fide good faith dispute, Ovamed
shall provide the Company with [*******] days written notice of such failure. The Company shall then have [*******] days from the date of such written notice in which to make the payment due. If payments are not so made within the time limit, Ovamed
may immediately terminate this Agreement by written notice. 
 9.3 In the event that the Company shall be in default in
the performance of any material obligations under this Agreement (other than as provided in 9.2 above which shall take precedence over any other default), and if the default has not been remedied within [*******] days after the date of notice in
writing of such default, Ovamed may terminate this Agreement immediately by written notice. 

  
 12.

 9.4 If the Company shall become bankrupt, or shall file a petition in bankruptcy and
such petition is not dismissed within [*******] days after it has been filed, or if the business of the Company shall be placed in the hands of a receiver, assignee or trustee for the benefit of creditors, whether by the voluntary act of the Company
or otherwise, this Agreement shall automatically terminate. 
 9.5 In the event that this Agreement is terminated due to
the Company’s breach, Company Sublicensee shall have at least [*******] days in which to bring this Agreement back into good standing. Should the nature of the activity associated with bringing this Agreement back into good standing reasonably
require more than [*******] days, then Ovamed shall grant Company Sublicensee additional time in which to bring this Agreement back into good standing. 
 9.6 The Company shall have the right to terminate this Agreement by giving thirty (30) days advance written notice to Ovamed to that effect. Upon termination, a final report shall be submitted and
any royalty payments and unreimbursed patent expenses due to Ovamed become immediately payable. 
 9.7 The Company shall
have the right during a period of six (6) months following the effective date of such termination to sell or otherwise dispose of the Licensed Product existing at the time of such termination, and shall make a final report and payment of all
royalties related thereto within sixty (60) days following the end of such period or the date of the final disposition of such inventory, whichever first occurs, 
 9.8 Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination or
obligations under Articles 4, 5, 12 and 16, for the exception of obligations under Articles 4.1.1 and 4.1.2. Ovamed hereby acknowledges and agrees that, should the Company terminate this Agreement within [*******] days after The pre-IND Meeting,
then the Company shall have no obligation to pay any amounts pursuant to Articles 4.1.1 and 4.1.2. The Company and/or any Company Sublicensee thereof may, however, after the effective date of such termination and continuing for a period not to
exceed [*******] months thereafter, sell all completed Licensed Products, and any Licensed Products in the process of manufacture at the time of such termination, and sell the same, provided that the Company shall pay or cause to be paid to Ovamed
the royalties thereon as required by Article 4 of this Agreement and shall submit the reports required by Article 5 hereof on the sales of Licensed Products. 
 9.9 If not terminated sooner, this Agreement shall terminate on the date of the last to expire valid claim contained in the Patent Rights in accordance with Section 2.1. 

9.10 Force Majeure: Neither party is responsible for delays resulting from causes beyond its reasonable control, including without
limitation fire, explosion, flood, war, strike, or riot, provided that the non-performing party uses commercially reasonable efforts to avoid or remove those causes of nonperformance and continues performance under this Agreement with reasonable
dispatch whenever the causes are removed. 

  
 13.

 ARTICLE 10 – ASSIGNMENT 

10.1 This Agreement and the rights and duties appertaining hereto may not be assigned by either party without first obtaining the
written consent of the other which consent shall not be unreasonably withheld. Any such purported assignment, without the written consent of the other party, shall be null and of no effect. Notwithstanding the foregoing, the Company may assign this
Agreement without the consent of Ovamed (i) to a purchaser, merging or consolidating corporation, or acquirer of substantially all of the Company’s assets or business and/or pursuant to any reorganization qualifying under section 368 of
the Internal Revenue Code of 1986 as amended, as may be in effect at such time, or (ii) to an Affiliate. 
 ARTICLE 11
– LIMITATION OF LIABILITY, INDEMNITY 
 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, OVAMED MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENTED RIGHTS CLAIMS, ISSUED OR PENDING. 

ARTICLE 12 – INDEMNIFICATION & INSURANCE 

12.1 The Company agrees to defend, indemnify and hold Ovamed harmless from and against all liability, demands, damages, including
without limitation, expenses or losses including death, personal injury, illness or property damage arising directly or indirectly: (a) out of use by the Company or its transferees of inventions licensed or information furnished under this
Agreement or (b) out of any use, sale or other disposition by the Company or its transferees of Patent Rights, Licensed Products or Licensed Processes, in each case which are not the result of Licensor’s breach of any representation or
warranty, negligence or willful misconduct. 
 12.2 Beginning at the time as any such product, process or service is
being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by the Company its Affiliate, or a Company Sublicensee, the Company shall, at its sole cost and expense procure and maintain comprehensive general
liability insurance in amounts not less than $[*******] per incident and $[*******] annual aggregate and naming UIRF as an additional insured. During clinical trials of any such product, process or service the Company shall, at its sole cost and
expense, procure and maintain comprehensive general liability insurance in such equal or lesser amounts as required by the License Agreement, naming UIRF as an additional insured. Such comprehensive general liability insurance shall provide
(i) product liability coverage and (ii) liability coverage consistent with the Company’s indemnification obligations under this Agreement. If the Company elects to self-insure all or part of the limits described above (including
deductibles or retentions which are in excess of $[*******] annual aggregate) such self-insurance program must be acceptable to UIRF. The minimum amounts of insurance coverage required shall not be construed to create a limit of the Company’s
liability with respect to its indemnification under this Agreement. 

  
 14.

 12.3 The Company shall provide Ovamed and/or UIRF (at the Company’s option) with
written evidence of such insurance upon request of Ovamed. The Company shall provide Ovamed and/or UIRF (at the Company’s option) with written notice at least [*******] days prior to the cancellation, non-renewal or material change in such
insurance; if the Company does not obtain replacement insurance providing comparable coverage within such [*******] day period, the Company shall have the right to terminate this Agreement effective at the end of such [*******] day period upon
written notice. 
 12.4 The Company shall maintain such comprehensive general liability insurance beyond the expiration
or termination of this Agreement during (i) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by the Company, its Affiliate or a Company
Sublicensee, and (ii) a reasonable period after the period referred to in (i) above which in no event shall be less than [*******]. 
 ARTICLE 13 – PAYMENT OF FEES AND EXPENSES 
 Each of the Company
and Ovamed shall be responsible for their own expenses relating to the preparation and consummation of this Agreement and the agreements and transactions contemplated hereby. 
 ARTICLE 14 – USE OF NAMES AND PUBLICATION 
 14.1 Nothing
contained in this Agreement shall be construed as granting any right to the Company or its Affiliates to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of Ovamed or any of its
units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of Ovamed; provided, however, that Ovamed acknowledges and agrees that the Company may use the name of Ovamed in various documents
used by the Company for capital raising and financing without such prior written consent and where the use of such names may be required by law. 
 14.2 Nothing herein shall be deemed to establish a relationship of principal and agent between Ovamed and the Company, nor any of their agents or employees for any purpose whatsoever. 

14.3 In the event that Ovamed desires to publish or disclose, by written, oral or other presentation, Patent Rights, Know-how, or
any material information related thereto then Ovamed shall notify the Company and in writing by facsimile where confirmed by the receiving party, and/or by certified or registered mail (return receipt requested) of their intention at least [*******]
days prior to any speech, lecture or other oral presentation and at least [*******] days before any written or other publication or disclosure. Ovamed shall include with such notice a description of any proposed oral presentation or, in any proposed
written or other disclosure, a current draft of such proposed disclosure or abstract. The Company may request that Ovamed, no later than [*******] days following the receipt of such notice, delay such presentation, publication or disclosure for up
to an additional [*******] days in order to enable the Company 

  
 15.

 
to file, or have filed on their behalf, a patent application, copyright or other appropriate form of intellectual property protection related to the information to be disclosed or request that
Ovamed do so. Upon receipt of such request to delay such presentation, publication or disclosure, Ovamed shall arrange for a delay of such presentation, publication or disclosure until such time as the Company or Ovamed have filed, or had filed on
its behalf, such patent application, copyright or other appropriate form of intellectual property protection in form and in substance reasonably satisfactory to the Company and Ovamed. If Ovamed does not receive any request from the Company to delay
such presentation, publication or disclosure, Ovamed may submit such material for presentation, publication or other form of disclosure. 
 ARTICLE 15 – PAYMENTS, NOTICES AND OTHER COMMUNICATIONS 
 Any
payment, notice or other communication required or permitted to be given pursuant to this Agreement shall be in writing and sent by certified first class mail, postage prepaid, by hand delivery or by facsimile if confirmed in writing, in each case
effective upon receipt, at the addresses below or as otherwise designated by written notice given to the other party: 
 In the
case of Ovamed: 
 Ovamed GbmH & Co KG 
 Attention: Mr. Detlev Goj, General Manager 
 Kiebitzhörn 33-35, 22885

 Barsbüttel, Germany 
 Tel: 49-40-67105710 
 In the case of the Company: 

Collingwood Pharmaceuticals, Inc. 
 787 Seventh Avenue, 48th Floor 
 New York, NY 10036 

Attn: President 

Tel: (212) 554-4300 
 Fax: (212) 554-4490 
 16. CONFIDENTIALITY 

16.1 Any proprietary or confidential information exchanged under this agreement (including, but not limited to, information
relating to the Patent Rights and royalty reports submitted pursuant to Article 5) constitute the “Confidential Information.” The Company and Ovamed agree that they will not use the Confidential Information for any purpose unrelated to
this Agreement, and will hold it in confidence during the term of this Agreement and for a period of [*******] years after the termination or expiration date of this Agreement. The parties shall exercise with respect to such the Confidential
Information the same degree of care as the parties exercise with respect to their own confidential or proprietary information of a similar nature, and shall not disclose it or permit its disclosure to any third party (except to those of its
employees, consultants, or agents who are bound by the same obligation of confidentiality as the parties bound by pursuant to this Agreement). However, such undertaking of confidentiality by the parties shall not apply to any information or data
which: 
 16.1.1 The receiving party receives at any time from a third-party lawfully in possession of same and having the right
to disclose same; 

  
 16.

 16.1.2 Is, as of the date of this Agreement, in the public domain, or subsequently enters
the public domain through no fault of the receiving party; 
 16.1.3 Is independently developed by the receiving party as
demonstrated by written evidence without reference to information disclosed by the disclosing party; 
 16.1.4 Is disclosed
pursuant to the prior written approval of the disclosing party; and 
 16.1.5 Is required to be disclosed pursuant to law or
legal process (including, without limitation, to a governmental authority) provided, in the case of disclosure pursuant to legal process, reasonable notice of the impending disclosure is provided to the disclosing party and the disclosing party has
agreed to such disclosure in writing or has exhausted its right to contest such disclosure. 
 ARTICLE 17 –
REPRESENTATIONS AND WARRANTIES 
 17.1 Ovamed represents and warrants that: 

17.1.1 Ovamed has all right and interest in and to the Patent Rights and Know-how, including the exclusive right and interest thereto,
free and clear of all liens, charges, encumbrances or other restrictions or limitations of any kind whatsoever. 
 17.1.2 There
are no licenses, options, restrictions, liens, rights of third parties, disputes, royalty obligations, proceedings or claims relating to, affecting, or limiting Ovamed’s rights or the rights of the Company under this Agreement, or which may
lead to a claim of infringement or invalidity regarding, any part or all of the Patent Rights or Know-how or their use. 

17.1.3 There is no claim, pending or threatened, of infringement, interference or invalidity regarding any part or all of the Patent
Rights or Know-how or their use. 
 17.1.4 The patent applications and patents itemized on Exhibit A set forth all of the
patents and patent applications relating to or useful for practicing the Technology in the Field of Use owned by or licensed by Ovamed on the Effective Date. 
 17.1.5 There are no inventors of Patent Rights other than those listed as inventors on Exhibit A. 
 17.1.6 The Patent Rights and Know-how were not supported in whole or part by funding or grants by any federal or state agency. 
 17.1.7 Ovamed has provided the Company with copies of all documents reflecting support or funding for all or part of the research leading to Patent Rights and Know-how, and has listed all such funding
agencies on Exhibit B. 

  
 17.

 ARTICLE 18 – MISCELLANEOUS PROVISIONS 

18.1 This Agreement shall be construed, governed, interpreted and applied in accordance with the Republic of Germany, without
regard to principles of conflicts of laws. 
 18.2 The parties hereto acknowledge that this Agreement, including the
Appendices and documents incorporated by reference, sets forth the entire agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change of modification except by the execution of a written
instrument subscribed to by the parties hereto and shall supersede all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. 

18.3 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to
be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof. 

18.4 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. Any waiver of any rights or failure to act in a specific instance relates only to that instance
and is not an agreement to waive any rights or fail to act in any other instance. 
 18.5 The headings of the several
articles are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
 18.6 This Agreement will not be binding upon the parties until it has been signed below on behalf of each party, in which event, it shall be effective as of the date recited on page one. As of the
Effective Date, this Agreement is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns. 
 18.7 Each party hereto shall be excused from any breach of this Agreement which is proximately caused by governmental regulation, act of war, strike, act of God or other similar circumstance
normally deemed outside the control of the parties. 

  
 18.

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by proper persons
thereunto duly authorized. 
  

									
	Collingwood Pharmaceuticals, Inc.	 		 	OVAMED GbmH & Co KG
					
	By:	 	 /s/ J. Jay Lobell
	 		 	By:	 	 /s/ Detlev Goj

									
			
	Name: J. Jay Lobell	 		 	Name: Detlev Goj
			
	Title: President	 		 	Title: Chief Executive Officer
			
	Date: December 12, 2005	 		 	Date: December 12, 2005

 Agreed as to Article 4.11: 
 Paramount Biosciences, LLC 
  

			
	By:	 	 /s/ Lindsay A. Rosenwald,
M.D.

			
	
	Name: Lindsay A. Rosenwald, M.D.
	
	Title: Managing Member
	
	Date: December 12, 2005

 Acknowledged 

University of Iowa Research Foundation 
  

			
	By:	 	 /s/ Pamela K. York

			
	
	Name: Pamela K. York
	
	Title: Executive Director
	
	Date: December 12, 2005

 [EXECUTION PAGE TO THE EXCLUSIVE SUBLICENSE AGREEMENT DATED DECEMBER     , 2005]

  
 19.

 Appendix A 
 The following comprise PATENT RIGHTS: 
 United States Patent Number 6,764,838 

United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249 
 Canada Patent Application Number 2,315,790 
 Japanese Patent Application Number 2000-526233

 Australia Patent Number 740776 

  
 20.

 Appendix B 
 National Institutes of Health / DHHS grant Identification Numbers [*******] 

  
 21.Manufacturing and Supply Agreement

 Exhibit 10.11 
 CONFIDENTIAL TREATMENT REQUESTED. 
 INFORMATION FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN 
 REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE 

CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS 

ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. 

MANUFACTURING AND SUPPLY AGREEMENT 
 by and among 
 COLLINGWOOD PHARMACEUTICALS, INC., 

and 
 OVAMED GMBH

 March 29, 2006 

 TABLE OF CONTENTS 

 

									
	1.	  	DEFINITIONS	  	 	1	  
	2.	  	MANUFACTURING AND SUPPLY AND PURCHASE	  	 	4	  
		  	2.1	  	Manufacturing	  	 	4	  
		  	2.2	  	Manufacturing Facilities	  	 	4	  
		  	2.3	  	Third Party Manufacturers	  	 	4	  
		  	2.4	  	Purchase Orders	  	 	4	  
		  	2.5	  	Inspection and Notifications	  	 	5	  
		  	2.6	  	Semi-Annual Relationship Review	  	 	6	  
		  	2.7	  	Documentation	  	 	6	  
	3.	  	DELIVERY, ACCEPTANCE, REJECTIONS.	  	 	6	  
		  	3.1	  	Delivery	  	 	6	  
		  	3.2	  	Acceptance and Rejection	  	 	7	  
		  	3.3	  	Late Delivery Credit	  	 	9	  
	4.	  	RECALLS, ADVERSE EVENT REPORTING, COMPLAINTS; REGULATORY	  	 	9	  
		  	4.1	  	Recalls	  	 	9	  
		  	4.2	  	Adverse Experience Reporting	  	 	10	  
		  	4.3	  	Complaints	  	 	11	  
		  	4.4	  	Regulatory Approvals	  	 	11	  
	5.	  	QUALITY AND CAPACITY	  	 	11	  
		  	5.1	  	Ovamed Representations, Warranties and Covenants	  	 	11	  
		  	5.2	  	Testing of Product for Conformance with Specifications	  	 	12	  
	6.	  	CHANGES IN SPECIFICATIONS OR MANUFACTURING PROCEDURES	  	 	12	  
		  	6.1	  	Sponsored Changes	  	 	12	  
		  	6.2	  	Impact on Inventory	  	 	13	  
	7.	  	PAYMENT	  	 	13	  
		  	7.1	  	Price	  	 	13	  
		  	7.2	  	Milestone Credit	  	 	14	  
		  	7.3	  	Payment	  	 	14	  
	8.	  	TERM AND TERMINATION	  	 	14	  
		  	8.1	  	Term	  	 	14	  
		  	8.2	  	Termination	  	 	15	  
		  	8.3	  	Survival	  	 	17	  
	9.	  	INDEMNIFICATION AND INSURANCE	  	 	17	  
		  	9.1	  	Ovamed Indemnification of Collingwood	  	 	17	  
		  	9.2	  	Collingwood Indemnification of Ovamed	  	 	17	  
		  	9.3	  	Insurance	  	 	18	  
	10.	  	LIABILITY	  	 	19	  
	11.	  	INTELLECTUAL PROPERTY	  	 	19	  
		  	11.1	  	Ownership of Intellectual Property	  	 	19	  
		  	11.2	  	Cooperation	  	 	19	  
		  	11.3	  	License of Ovamed Intellectual Property Rights	  	 	19	  
	12.	  	CONFIDENTIAL INFORMATION	  	 	20	  
		  	12.1	  	Confidentiality	  	 	20	  
		  	12.2	  	Authorized Disclosure	  	 	20	  
		  	12.3	  	No Confidential Information of Other Parties	  	 	21	  
		  	12.4	  	Equitable Relief	  	 	21	  

  
 -i-

									
	13.	  	MISCELLANEOUS	  	 	21	  
		  	13.1	  	Correspondence and Notices	  	 	21	  
		  	13.2	  	Compliance with the Laws; Permits and Licenses	  	 	22	  
		  	13.3	  	Assignment	  	 	22	  
		  	13.4	  	Force Majeure	  	 	23	  
		  	13.5	  	Use of Name	  	 	23	  
		  	13.6	  	Language of the Agreement	  	 	23	  
		  	13.7	  	UN Convention on Contracts for Sale of Goods	  	 	23	  
		  	13.8	  	Amendment	  	 	23	  
		  	13.9	  	Waiver	  	 	24	  
		  	13.10	  	Severability	  	 	24	  
		  	13.11	  	Descriptive Headings	  	 	24	  
		  	13.12	  	Governing Law	  	 	24	  
		  	13.13	  	Jurisdiction; Venue; Service of Process	  	 	24	  
		  	13.14	  	Entire Agreement	  	 	25	  
		  	13.15	  	Conflicts	  	 	25	  
		  	13.16	  	Independent Contractors	  	 	25	  
		  	13.17	  	Counterparts	  	 	25	  

  

			
	SCHEDULES AND EXHIBITS
		
	Exhibit A	  	Specifications
		
	Exhibit B	  	Work to be Performed
		
	Exhibit C	  	Raw Materials Index
		
	Exhibit D	  	Form of certificate of analysis
		
	Exhibit E	  	Clinical Plan for the Product

  
 -ii-

 MANUFACTURING AND SUPPLY AGREEMENT 

This Manufacturing and Supply Agreement (the “Agreement”) is entered into this      day of
December, 2005 (the “Effective Date”), by and between Collingwood Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (“Collingwood”),
and Ovamed GmbH, a corporation organized and existing under the laws of Germany and having a principal place of business at Kiebitzhörn 33-35, 22885 Barsbüttel, Germany (“Ovamed”). Collingwood and Ovamed may each be
referred to herein individually as a “Party” and collectively as the “Parties.” 
 Recitals

 A. Collingwood wishes to engage Ovamed to manufacture Products (as defined below) and supply them to Collingwood as an
active pharmaceutical ingredient and drug product for preclinical, clinical and commercial use. 
 B. Ovamed desires to
manufacture Products and supply them to Collingwood and Collingwood desires to purchase Products from Ovamed for such use as further described and in accordance with the terms and conditions of this Agreement. 

C. Ovamed has obtained an exclusive license (the “License”) from the University of Iowa Research Foundation
(“UIRF”) to practice certain patent rights in the United States, Canada, Japan, and Australia; 
 D.
Collingwood and Ovamed have entered an Exclusive Sublicense Agreement (the “Sublicense”), under which Ovamed granted to Collingwood an exclusive right to practice the patent rights discussed in the License in connection with the
prevention, treatment, cure or diagnosis of human diseases, with the exception of gastroenterology (e.g., inflammatory bowel disease) and hepatology in Europe (the “Field of Use”). 

Agreement 

NOW THEREFORE, the parties agree as follows: 
 1. DEFINITIONS 
 Capitalized terms used but not defined in this Agreement have the meanings
given to them as set forth below. 
 “Acceptance” has the meaning given to it in Section 3.2.1.

 “Approved Subcontractor” means, at any time, any member of the Ovamed Group or other subcontractor engaged
by Ovamed for the manufacture or supply of a principal component necessary for the manufacture of Product reasonably acceptable to Collingwood. 
 “Affiliate” of any person shall mean any general or limited partner of any such person that is a partnership, member of any such person that is a limited liability company or any person
or entity that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such person. 

  
 - 1 -

 “CGMP” means Current Good Manufacturing Practices, as defined in a
regulation in 21 CFR § 210, 211, or 600 or, as applicable, the applicable European Agency for the Evaluation of Medicinal Products (“EMEA”) Guidelines, or any other rules or regulations which may be applicable in any
jurisdiction in which Ovamed manufactures the Product pursuant to this Agreement. 
 “Change Request” means a
written request for a change to a Specification. 
 “Competing Party” means any third party manufacturing,
developing, or commercializing a product approved or intended to be approved by a Regulatory Authority for use within the Field of Use which includes the use of TSO. 
 “Confidential Information” means all information relating to a Party, its business or prospects (including, without limitation, data, know-how, trade secrets, business plans), disclosed
by such Party from time to time to the other Party in any manner, whether orally, visually or in tangible form (including, without limitation, documents, devices and computer readable media) and all copies thereof, created by either party.

 “Developments” has the meaning given to it in Section 11.1. 

“Disclosing Party” has the meaning given to it in Section 12.1. 

“FDA” means the United States Food and Drug Administration. 

“Field of Use” has the meaning given to it in the Recitals. 

“IND Milestone Payments” has the meaning given to it in Section 7.2. 

“Intellectual Property Rights” means patents, copyrights, design rights, trademarks, service marks, trade names, trade
secrets, know-how, and other intellectual property rights of any kind and nature. 
 “Late Delivery Credit” has
the meaning given to it in Section 3.3. 
 “Liabilities” means any liability, loss, damage, claim, cost or
expense (including reasonable fees of attorneys and other professionals and court costs). 
 “License” has the
meaning given to it in the Recitals. 
 “Minimum Batch Size” will be mutually agreed to by the parties in
writing in the event of changes to the Product pursuant to Article 6 below. There will be no Minimum Batch Size prior to any such entered agreement. 

  
 - 2 -

 “Ovamed Competitor” means any direct competitor of Ovamed that
(i) sells TSO and (ii) sells a product that directly competes with a product sold by Ovamed that constitutes [*******]% or more of Ovamed’s net revenues. 
 “Ovamed Group” means Ovamed and its Affiliates. 

“Products” means initially TSO manufactured in accordance with the Specifications, or as otherwise mutually agreed by
the Parties in the event changes are made to the Product pursuant to Article 6 below. 
 “Purchase Order” means
a written purchase order submitted to Ovamed by Collingwood or one of its affiliates under this Agreement for delivery of Products; provided that any terms and conditions contained or incorporated by reference in any such purchase order that
conflict with the terms and conditions of this Agreement or the attachments made a part hereof shall be of no force or effect whatsoever concerning the subject matter of this Agreement, and Ovamed’s failure to object thereto shall not be deemed
a waiver of Ovamed’s rights hereunder. 
 “Receiving Party” has the meaning given to it in
Section 12.1. 
 “Regulatory Approval” means with respect to a nation or multinational jurisdiction any
approvals, licenses, registrations or authorizations necessary for the manufacture, marketing and sale of the Product in such nation or jurisdiction. 
 “Regulatory Authority” means any federal, state or foreign government authority. 
 “Regulatory Information” means the following information (or the equivalent in any relevant non-United States jurisdiction): IND Safety Reports & Follow-ups (21 CFR
§312.32(c)&(d)), Post-marketing 15-day Alert Reports & Follow-ups (21 CFR §314.80(c)1), Periodic Adverse Drug Experience Reports (21 CFR §314.80(c)2), Field Alert Reports (21 CFR §314.81(b)(1)), Product Complaints
(21 CFR §211.198), IND Annual Reports (21 CFR §312.33(b)) and Post-marketing Annual Reports (21 CFR §314.81(b)(2)(i),(iv)&(v)). 
 “Specifications” means the finished product specifications for the Products and testing standards and procedures to be employed in determining compliance therewith attached hereto as
Exhibit A, as amended from time to time in accordance with this Agreement. 
 “Sublicense” has the meaning
given to it in the Recitals. 
 “Term” has the meaning given to it in Section 8.1. 

“Territory” means the entire world, to the extent Ovamed possesses a license to practice the Patent Rights (as defined
in the Sublicense) in specific countries and/or territories in the world. 
 “Transfer Assistance” has the
meaning given to it in Section 8.3. 
 “TSO” means Trichuris suis ova. 

  
 - 3 -

 “UIRF” has the meaning given to it in the Recitals. 

“Unit” means approximately [*******], or such other final dose as approved by the relevant Regulatory Authority, on the
basis that a treatment dose will require [*******] Units per year and maintenance dose will require [*******] Units per year. 

“Withdrawal Notice Date” has the meaning given to it in Section 8.2.5. 

2. MANUFACTURING AND SUPPLY AND PURCHASE. 
  

	 	2.1	Manufacturing. 

 Ovamed
agrees to manufacture and supply, and Collingwood agrees to purchase, Product solely for non-clinical, clinical and commercial use in the Field of Use in the Territory, according to the terms of this Agreement. Ovamed also agrees to engage in
development with Collingwood in connection with the Products as part of a Change Request pursuant to the terms and conditions as set forth in Section 6.1.1 of this Agreement. 

 

	 	2.2	Manufacturing Facilities.  

 In addition to the existing manufacturing facility in Germany, Ovamed shall establish at least two (2) more manufacturing facilities located in the United States, which will be in compliance with
CGMP and the first of which will be completed and operational upon [*******]. Ovamed will establish a second manufacturing facility located in the United States, which will be completed and operational prior to the [*******]. Upon the establishment
of the United States manufacturing facilities and any others, and on each twelve-month anniversary thereof, Ovamed will provide to Collingwood written certification that all manufacturing facilities in the United States at which Product is
manufactured are in compliance with CGMP and that all manufacturing facilities existing outside of the United States at which Product is manufactured are in compliance with the relevant regulations of such jurisdiction. 

 

	 	2.3	Third Party Manufacturers. 

Ovamed shall remain responsible for its obligations under this agreement notwithstanding any delegation hereunder. 

 

	 	2.4	Purchase Orders.  

All orders placed by Collingwood for the Products require a Purchase Order. Collingwood shall submit to Ovamed a [*******] month rolling
supply forecast in writing and a firm Purchase Order for the purchase of any Products at least [*******] days prior to the specified delivery date in writing, and Ovamed shall accept such Purchase Order in writing, subject to the adherence of such
Purchase Order to the terms and conditions of this Agreement. Each Purchase Order shall be signed by an employee of Collingwood and specify the quantity of Products ordered, the purchase price, the requested delivery date or dates, and delivery
locations. Ovamed reserves the right to cancel, suspend, refuse or delay any orders if Collingwood fails to make any payment when due, and such failure continues after [*******] days notice of such non-payment

  
 - 4 -

 
from Ovamed. At the reasonable request of Ovamed, Collingwood will cooperate and submit to Ovamed any information required for Ovamed to obtain “accounts receivable insurance” from a
bona fide third party carrier (such information will be restricted to information that is customarily required for such types of insurance). 
  

	 	2.5	Inspection and Notifications. 

 2.5.1 Inspections. During regular business hours and upon reasonable advance notice, Ovamed shall permit, and upon reasonable notice and coordination of schedules shall use reasonable
efforts to cause each of its Approved Subcontractors to permit, Collingwood, its consultants and/or contractors reasonably acceptable to Ovamed (or if not reasonably acceptable to Ovamed, Ovamed will supply a list of appropriately qualified
consultants acceptable to it for Collingwood to use) and government personnel (including without limitation personnel from the FDA, for whom advance notice is not required, or any other Regulatory Authority in the Territory) to inspect the
facilities of Ovamed and each of its Approved Subcontractors and to review manufacturing activities related to the Products solely to the extent necessary for, and for the purpose of assessing Ovamed’s regulatory and quality compliance with,
CGMP and for the purpose of determining compliance with the Specifications; provided that, (i) Collingwood shall not be permitted to exercise its right of inspection under this Section more than [*******] times in any twelve month period
(ii) such restriction on the number of inspections shall not apply to governmental inspections, (iii) each party conducting an inspection, other than governmental, shall execute with Ovamed a nondisclosure agreement containing a
conventional penalty in case of breach not less than € [*******], reasonably acceptable to Ovamed with regard to all materials inspected. Ovamed shall permit, and use reasonable efforts, to cause each of its Approved Subcontractors to
permit, Collingwood and government personnel, to review and make copies of all relevant documents related to the Products that might reasonably be requested for such purposes. The costs of Ovamed’s reasonable expenses incurred in connection
with such inspections, shall be borne by Collingwood. 
 2.5.2 Notification. Ovamed shall promptly
provide Collingwood notice of all inspections of Ovamed’s facilities by any Regulatory Authority reasonably related to Ovamed’s performance hereunder or the subject matter of this Agreement, and each Party shall promptly provide the other
Party with notice of all (A) written claims and allegations, and (B) claims and allegations made orally that reasonably appear to warrant investigation or response, in either case of which Ovamed or Collingwood is aware, that Ovamed is not
complying with CGMP or with the relevant Specifications. The obligations of this Section apply equally to any such notices provided to Ovamed’s Approved Subcontractors to Ovamed’s knowledge. 

  
 - 5 -

 2.5.3 Records. Ovamed shall maintain all of its manufacturing
and analytical records, all records of shipments of Products and all reasonable validation data relating to Products for a minimum of five (5) years from Product shipment. Collingwood shall maintain all of its sales, and analytical records, all
records of shipments of Products and all reasonable validation data relating to Products for a minimum of two (2) years from Product shipment. Each Party agrees that, in response to any complaint, or in the defense by the other Party of any
litigation, hearing, regulatory proceeding or investigation relating to any Products, it shall make available to the other Party, at the other Party’s cost and expense, such employees and records reasonably necessary to permit the effective
response to, defense of, or investigation of such matters, subject to appropriate confidentiality protections and such records shall be deemed Confidential Information of the disclosing party hereunder. 

 

	 	2.6	Semi-Annual Relationship Review. 

 The Parties will meet or speak by telephone during the last month of each semi-annual period following the Effective Date and at such other times as mutually agreed upon by the parties, to review their
relationship and performance under this Agreement, including but not limited to, review of the Specifications. This review will not give rise to any amendment to the Agreement other than pursuant to Section 13.8 hereunder. 

2.7 Documentation. Ovamed will supply all reasonable documentation related to the Products to support Collingwood’s
effort to obtain and maintain Regulatory Approval for the Sale of Products that is required to comply with guidance documents and regulations of Regulatory Authorities that is relevant to biological agents for human use (the
“Documentation”). To the extent that the Documentation required to be supplied by Ovamed under this Section is documentation, or is substantially the same as documentation, that Ovamed has, at the time, in its possession, then
Ovamed shall supply such Documentation without any additional charge to Collingwood; otherwise, Collingwood shall pay to Ovamed an amount equal to Ovamed’s fully burdened costs, including, but not limited to, overhead, incurred in performing
the work required to prepare such Documentation. 
 3. DELIVERY, ACCEPTANCE, REJECTIONS. 

 

	 	3.1	Delivery. 

3.1.1 Delivery. Ovamed shall deliver all Products ordered under this Agreement corresponding to the
quantities, delivery dates and delivery locations set forth in each Purchase Order provided to Ovamed pursuant to and in accordance with Section 2.3. All Products shipped pursuant to the terms of this Agreement shall be manufactured not more
than [*******] months preceding the shipment date, labeled and packed for shipment in accordance with the Specifications set forth on Exhibit A, and shall be marked for shipment to the designated location specified in the Purchase Order. All
deliveries of Products will be to the designated location specified in the Purchase Order. Ovamed will have no further responsibility for Products after, and all risk of damage to or loss or delay of Products will pass to Collingwood upon, delivery
by Ovamed to the designated carrier. The prices of the Products include all palletizing, packing, crating and storage charges at Ovamed facility, other than as set forth in Section 

  
 - 6 -

 
3.1.2 below. Collingwood will pay for all freight, insurance and other shipping expenses incurred during shipment to the designated location and Ovamed shall be responsible for clearing the
Product for import, export and for other customs matters. Both parties (Ovamed and Collingwood) shall consult with each other in advance of each shipment and shall cooperate with each other to permit Ovamed to make suitable shipping, insurance,
customs and related arrangements. Ovamed shall obtain all appropriate approvals and consents of any governmental authority in the United States or other relevant jurisdictions, as applicable, necessary for the manufacture (including packaging), and
exportation from the place of manufacture of the Products to Collingwood and Ovamed shall comply with all applicable laws and regulations pertaining thereto. 
 3.1.2 Except to the extent resulting from Ovamed’s failure to comply with its obligations under this Agreement, Collingwood will bear the actual and reasonable costs (including storage) resulting
from Collingwood’s failure to receive Products at scheduled times. 
  

	 	3.2	Acceptance and Rejection. 

 3.2.1 Acceptance. Ovamed will provide Collingwood with a certificate of analysis for each invoiced Product substantially in the form of Exhibit D. Each shipment of Product will be deemed
accepted by 5:00 p.m. EST on the [*******] day after receipt by Collingwood unless Collingwood notifies Ovamed prior to such time that the shipment (i) contains any discrepancy between the actual quantity of Product supplied and the quantity of
Product quoted in the supply documents delivered with the applicable Products, (ii) is incorrectly invoiced, or (iii) does not contain a certificate of analysis showing conformity of the Product with the Specifications. The shipment will
be deemed rejected upon delivery of such notice by Collingwood; provided, however, if the original shipment of the Product is found to be conforming, then Collingwood shall pay to Ovamed any due amount plus interest in the amount of
[8]% per year of the unpaid amount. Each shipment of Product(s) accepted by Collingwood under this Agreement will be subject to inspection and performance testing by Collingwood within a period of [*******] days after receipt of a particular
shipment of Product(s) (as applicable, the “Inspection Period”) to determine whether the Product(s) in such shipment complied at the time of delivery to the carrier at Ovamed’s facilities with the Specifications and any applicable
warranties under this Agreement. Collingwood shall promptly, but in no event more than [*******] days after the Inspection Period (the “Notice Period”), notify Ovamed if any particular shipment did not so comply with the
Specifications or applicable warranties at the time of delivery to the carrier. Upon request by Collingwood, during the Inspection Period, Ovamed will promptly provide copies of completed batch records (including deviations and corrective actions),
and Collingwood shall pay for the actual costs of copying and sending such batch records on a cost basis. If Collingwood and Ovamed reasonably determine that the Product(s) did not comply with the Specifications or the applicable warranties under
this Agreement at the time of delivery to the carrier, Collingwood shall promptly notify Ovamed 

  
 - 7 -

 
of such non-compliance, but in no event more than the later of (x) [*******] days after Collingwood’s receipt of all such completed batch records or (y) the expiration of the
Notice Period. If the Parties are unable to agree on whether such non-compliance has occurred within [*******] days, then the Parties shall promptly engage a third party testing laboratory, mutually agreed upon and that shall enter into a
confidentiality Agreement with Ovamed and Collingwood, to determine whether such non-compliance has occurred prior to the delivery of Product(s) to the carrier. The costs of such third party testing laboratory shall be borne by Collingwood, unless
such third party testing laboratory determines that the particular shipment of Product was non-compliant at Ovamed’s facilities at the time of delivery to the carrier, in which case such costs shall be borne by Ovamed. If Collingwood does not
deliver written notice to Ovamed during the Notice Period that Collingwood rejects such shipment because of a non-compliance at the time of delivery to the carrier at Ovamed’s facilities, Collingwood will be deemed to have accepted the
shipment, subject to any right it may have under law or this Agreement. 
 3.2.2 Replacement; Expenses.
If a Product shipment is rejected by Collingwood under Section 3.2.1(iii) or because such shipment did not comply at the time of delivery to the carrier with the Specifications and any applicable warranties under this Agreement as set forth
in Section 3.2.1 above (subject to the dispute resolution procedure set forth therein), then Collingwood may, at its discretion, either (i) obtain a credit or refund, in [*******]’s sole discretion, for the amount paid by Collingwood
for the non-conforming Product or (ii) require Ovamed to correct or replace, in [*******]’s sole discretion, the non-conforming Product so that it complies. If Collingwood requests, Ovamed agrees to correct or replace any such Product as
soon as is practicable but no later than [*******] days after Collingwood’s request for such correction, and will bear all reasonable expenses of making such corrections. If Ovamed is unable to so correct or replace the Product within such
[*******] day period, it will so notify Collingwood no later than [*******] days after the end of such [*******] day period, whereupon Collingwood will have the option, at its sole discretion, to (x) require Ovamed to credit Collingwood for the
amount paid by Collingwood for such Product or (y) require Ovamed to use all commercially reasonable efforts to promptly replace the Product at Ovamed’s expense. Upon Ovamed’s request and at Ovamed’s expense Collingwood shall
return or dispose of the non-conforming Products. Without limiting the foregoing, Ovamed will reimburse or credit Collingwood for any costs or expenses paid by Collingwood at the instructions of Ovamed or as required by relevant regulations related
to the return, repair or destruction of the non-conforming Product(s). Notwithstanding the foregoing, if the original shipment of Product is found to be conforming, then Collingwood shall pay for the replacement shipment in accordance with the terms
of this Agreement plus interest as applicable to late payment. Any credit or refund due under this Section will bear interest, which shall accrue at an annual percentage rate equal to the lesser of [*******] percent ([*******]%) per month or the
maximum rate allowable by law at the date of such credit or refund is due until such refund is paid or such credit is used. 

  
 - 8 -

	 	3.3	Late Delivery Credit. 

 3.3.1 Credit. Subject to a Force Majeure Event, if Ovamed fails to deliver any Products within [*******] days after the delivery date specified in an accepted Purchase Order to the
designated location specified in the Purchase Order, Ovamed will give Collingwood a credit to be applied to the purchase price owed for such Product(s) (a “Late Delivery Credit”); provided, that (a) such credit shall be applied
to future payments due by Collingwood under this Agreement, if any; and (b) except as set forth in Section 8.2.1 and 8.2.2, such Late Delivery Credit shall be Collingwood’s sole and exclusive remedy for any such delay. The amount of
the Late Delivery Credit will vary based on the number of days a delivery follows the date specified in the accepted Purchase Order, and will equal the following percentage of the purchase price for the Product(s) that is delivered late: 

 

			
	 Number of Days Late
	  	 Late Delivery Credit

	 [*******]
	  	 [*******]% of the purchase price for late Product

	 [*******]
	  	 [*******]% of the purchase price for late Product

	 [*******]
	  	 [*******]% of the purchase price for late Product

 Collingwood may apply the Late Delivery Credit to reduce the amount due to Ovamed under the invoice for
late-delivered Product. In the event that Ovamed knows that any Product being shipped to Collingwood will be delivered more than [*******] after the delivery date specified in the accepted Purchase Order for such Product due to reasons that are
within Ovamed’s control, Ovamed will note the Late Delivery Credit that applies to that Purchase Order in the invoice for that Purchase Order. 
 4. RECALLS, ADVERSE EVENT REPORTING, COMPLAINTS; REGULATORY. 
  

	 	4.1	Recalls. 

4.1.1 Recalls of Product. Collingwood shall promptly notify Ovamed of any recall, product withdrawal, or
field correction to the Product, and provide copies of all press releases related to such action, whether or not effected voluntarily or requested or ordered by any federal or state agency or government agency. Ovamed may recommend a recall, product
withdrawal or field correction, however, subject to Ovamed’s obligation to adhere to all applicable laws and regulations, the decision to conduct such an activity shall be Collingwood’s alone. Ovamed shall reasonably cooperate with
Collingwood as necessary to effectuate any such recall, withdrawal or correction, at Collingwood’s sole cost and expense. Subject to applicable law, regulation or Regulatory Authority request, Collingwood or its designee shall make all contacts
with the FDA and any other regulatory agencies, shall be responsible for coordinating all of the necessary activities in connection with such recall, product withdrawal, or field correction and shall make any statements to the media,

  
 - 9 -

 
including, but not limited to, press releases and interviews for publication or broadcast related to such recall, product withdrawal, or field correction; provided that, Collingwood will
provide Ovamed written notice concurrently or as soon as practicable after Collingwood makes any statement to the FDA, regulatory agency, media and/or to the public related to a recall, product withdrawal, or field correction that specifically
refers to Ovamed or is reasonably related to any of the Products, which sets forth such statement. Ovamed will reasonably cooperate with Collingwood in the conduct of such activities. Collingwood shall keep Ovamed fully informed of progress and
shall consult with Ovamed in relation to all material decisions or actions as may reasonably relate to a recall, product withdrawal, or field correction of the Products. 

4.1.2 Recall Expense. Ovamed shall bear the full expense of both Parties incurred in any recall, withdrawal
or correction of the Product resulting from (i) failure of any Product to meet the Specifications at the time of delivery of such Product by Ovamed to the carrier, or (ii) Ovamed’s failure to manufacture any Product in accordance with
CGMP and all other applicable laws, and Collingwood shall bear the full expense of both Parties incurred in any other recall, withdrawal or correction of the Product. Any dispute between the Parties as to which Party is responsible for a defect will
be made by an independent arbitrator, mutually satisfactory to the Parties, and having sufficient scientific and manufacturing skills necessary to adjudicate upon the matter in dispute. The costs of such arbitrator will be borne by the Party against
whom the arbitrator rules. Such expenses of recall shall include, without limitation, the expenses of notification and destruction or return of the recalled Product and the sum paid by a third party for the recalled Product. In the event, however,
that a recall is partially caused by reasons as set forth in subsections (i) and/or (ii) of this Section 4.1.2 and partially for other reasons, then each Party shall be responsible for its proportionate share of the recall expenses
based on its proportionate share of causation. 
  

	 	4.2	Adverse Experience Reporting.  

 Each Party shall cooperate with the other Party and provide all assistance reasonably requested by the other Party for the other Party to respond in a timely fashion to Regulatory Authorities in the event
of product complaints, Field Alert Reports, SUSARs, or Adverse Event reports which require submission to Regulatory Authorities as expedited reports, e.g., 15-day Alert Reports or in other regulatory submissions including but not limited to IND
Annual Reports and NDA/BLA Annual Reports or Periodic Safety User reports, each as defined by the applicable Section of the U.S. Code of Federal Regulations, in accordance with current FDA and any other applicable guidance and regulations, including
without limitation providing to the other Party all Regulatory Information in its possession reasonably required for FDA compliance. Each Party may use such information to meet its respective legal and regulatory obligations. The capitalized terms
used in this Section but not defined in this Agreement shall have the customary meaning under current FDA and European Union guidance and regulations. 

  
 - 10 -

	 	4.3	Complaints.  

Unless otherwise required by law, Collingwood shall have sole responsibility and authority to respond to any customer or other complaints
with respect to the Products or other aspects of the Product; provided, however, Collingwood will provide Ovamed written notice concurrently with or as soon as practicable after Collingwood makes any statement to such complaining party, the FDA,
regulatory agency, media and/or to the public in response to any complaint that may be reasonably related to the Products that specifically refers to Ovamed or any of the Products, which sets forth such statement. Except as otherwise provided
herein, Ovamed will not be liable or made responsible for any act or cost incurred or committed by Collingwood in connection with any action taken by Collingwood under this Section. Each Party shall promptly advise the other Party of all relevant
details if it receives any complaints pertaining to the Product. Collingwood shall promptly advise Ovamed of all relevant details if it receives any significant complaints pertaining to the Product (except that any complaints pertaining to the
Product that require a report to a Regulatory Authority shall be deemed to be significant), and Ovamed shall promptly advise Collingwood of all relevant details if it receives any significant complaints pertaining to the Product (except that any
complaints pertaining to the Product that require a report to a Regulatory Authority shall be deemed to be significant). Subject to the foregoing, Ovamed shall provide reasonable cooperation and assistance to Collingwood in responding to complaints
with respect to the Products. 
  

	 	4.4	Regulatory Approvals.  

 The Parties shall fully cooperate in good faith, and shall provide all reasonable assistance and information, in a timely manner, to each other, to obtain and maintain all Regulatory Approvals that are
required to manufacture, distribute, use or sell the Products, including without limitation the preparation, filing and maintenance of any U.S. Biological License Application or European Marketing Authorization (or equivalent in other
jurisdictions). If there are incremental regulatory filing fees that are applicable to the Products, Collingwood will bear such regulatory fees. The parties shall also reasonably assist each other in responding to requests and inquiries from
applicable Regulatory Authorities prior to, during and after regulatory review periods, including without limitation, providing all data, records and reports required in order to comply with the regulatory Authority request. 

5. QUALITY AND CAPACITY. 
  

	 	5.1	Ovamed Representations, Warranties and Covenants. 

 Ovamed hereby represents, warrants and covenants to Collingwood that the Products [*******]: (a) shall be manufactured in compliance with CGMP and all other applicable regulatory and governmental
regulations, as applicable; (b) shall conform to the certificates of analysis supplied with each shipment pursuant to Section 5.2; and (c) shall be free and clear of any lien or encumbrance and Ovamed will have all rights necessary to
transfer title to the Products to Collingwood. The foregoing warranty shall not apply to the extent that the Product has been subject to use or other conditions not in accordance with the applicable Specifications, or has otherwise been the subject
of mishandling, misuse, neglect, alteration or damage by the carrier or Collingwood. 

  
 - 11 -

	 	5.2	Testing of Product for Conformance with Specifications.  

 Ovamed will test each batch of the Products supplied to Collingwood under this Agreement and provide Collingwood with a written certificate of analysis (in the form set forth in Exhibit D) along with each
batch of Products that confirms that such Product meets the Specifications and warranties under this Agreement. Collingwood may retest each batch of Products and perform other performance measurements in accordance with Section 3.2.1 of this
Agreement to confirm that such batch meets the applicable Specifications and warranties in accordance with this Agreement. 
 6. CHANGES IN
SPECIFICATIONS OR MANUFACTURING PROCEDURES. 
  

	 	6.1	Sponsored Changes. 

 6.1.1 Changes Sponsored by Collingwood. Collingwood shall notify Ovamed in writing of a Change Request proposed by Collingwood no less than 180 days prior to the proposed effective date for
the Change Request. The notification shall include a description of the proposed changes, information regarding medical, clinical, and regulatory factors and the proposed implementation date. Notification shall also include the reasonably
appropriate documentation to support Ovamed’s investigation of the impact of this proposal. Ovamed may review the feasibility of the implementation and any other aspect of the proposed Change Request. Ovamed shall use commercially reasonable
efforts to advise Collingwood of its decision with respect to the proposed Change Request as soon as practicable but in any case no later than within 120 days after receipt of Collingwood’s written notification. No Change Request shall be made
by Collingwood without Ovamed’s prior written approval, which approval may be provided or withheld in Ovamed’s reasonable discretion. Until a Change Request has been agreed to in writing by both Parties, the Change Request shall not be
effective, and the Parties shall continue to perform their obligations under the then-effective Specifications. Any change that is in connection with the Minimum Batch Size and in connection with a mandatory change resulting from a Regulatory
Authority communication, shall not be considered a Change Request sponsored by Collingwood. 
 6.1.2 Changes
Sponsored by Ovamed. Ovamed shall notify Collingwood in writing of a Change Request proposed by Ovamed no less than 180 days prior to the proposed effective date for the Change Request. If so proposed, Ovamed will provide Collingwood with
samples of Product that incorporates or is a result of the Change Request. The notification shall include a description of the proposed changes, information regarding medical, clinical, and regulatory factors and the proposed implementation date.
Notification shall also include the reasonably appropriate documentation to support Collingwood’s investigation of the impact of this proposal. Collingwood may review the feasibility of the implementation and any other aspect of the proposed
Change Request. Collingwood shall use commercially reasonable efforts to advise Ovamed of its decision with respect to the proposed Change Request as soon as 

  
 - 12 -

 
practicable but in any case no later than within 120 days after receipt of Ovamed’s written notification. No Change Request shall be made by Ovamed without Collingwood’s prior written
approval, which approval may be provided or withheld in Collingwood’s reasonable discretion. Until a Change Request has been agreed to in writing, the Change Request shall not be effective, and the Parties shall continue to perform their
obligations under the then-effective Specifications. Any change that is in connection with the Minimum Batch Size and in connection with a mandatory change resulting from a Regulatory Authority communication, shall not be considered a Change Request
sponsored by Ovamed. 
 6.1.3 FDA Agreement. To the extent that a Change Request accepted or
proposed by Collingwood will require any filing with any Regulatory Authority or the granting of any Regulatory Approval for the Product, each Party shall reasonably cooperate with each other and take all reasonable actions and provide all
information as may be reasonably requested by Collingwood or Ovamed in connection with preparing such filings and obtaining such Regulatory Approval. Costs incurred by Ovamed in connection with the above will be subject to the terms of Sections
6.1.1 and 6.1.2 above. Without limiting any other provision of this Article 6, Ovamed will not change any aspect of the Product or the process by which the Product is manufactured that requires the FDA approval if the FDA does not provide written
confirmation, prior to making the change, that the change will not terminate or otherwise impair any Regulatory Approval for the Product. Collingwood will support and assist Ovamed in any communications with the FDA that may be required as described
above in order to achieve such FDA confirmation. 
  

	 	6.2	Impact on Inventory. 

 Any
agreed modification following a Change Request shall only take effect once all Product manufactured pursuant to the previous Specifications and already scheduled for delivery has been delivered under the terms of this Agreement. 

7. PAYMENT. 
  

	 	7.1	Price. 

 In consideration
of Ovamed’s manufacture and supply of Products hereunder, Collingwood shall pay to Ovamed an amount equal to the total number of Units delivered in each calendar quarter (the “Actual Amount”) multiplied by the corresponding Price (per
Unit), as defined in the following sentence, minus any Late Delivery Credit owed to Collingwood under Section 3.3 of this Agreement (the “Interim Amount”). On the Effective Date of this Agreement, the “Price” shall be
$[*******] per Unit for clinical supplies and $[*******] per Unit for commercial supplies. During the Term, Ovamed will use commercially reasonable efforts to decrease the cost of goods sold to Collingwood (as determined in accordance with generally
accepted accounting principles, consistently applied). Ovamed will promptly notify Collingwood of any such decreases and the Price shall be decreased by [*******]% of any such decrease in cost of goods sold. In case the FDA or other official
Regulatory Authority mandates that more than [*******] Units 

  
 - 13 -

 
to be dosed to the patient Collingwood shall not be required to pay an amount greater than: (i) [*******] Dollars ($[*******]) per patient per year for total commercial supplies of Units in
the first year in which Units are administered to a patient; and (ii) [*******] Dollars ($[*******]) per patient per year for total commercial supplies of Units in any subsequent year following the first year in which Units are administered to
a patient. 
  

	 	7.2	Milestone Credit. 

 So
long as Collingwood makes the milestone payments to Ovamed which are set forth in Sections 4.3.1 and 4.3.2 of the Sublicense (the “IND Milestone Payments”), Ovamed will give Collingwood a credit, said credit not to exceed [*******]
Dollars ($[*******]), to be applied to the purchase price owed for any Units purchased for clinical supplies of Products up to the aggregate amount of the IND Milestone Payments. To the extent that the aggregate amount of IND Milestone Payments
exceeds the aggregate purchase price of clinical supplies, any excess will be applied as a credit against the purchase price of any commercial supplies of Products. 
  

	 	7.3	Payment. 

 Ovamed will
invoice Collingwood for Products upon delivery. Amounts owed under invoices shall be due and payable in U.S. currency within [*******] days after date of such invoice, subject to the offset described in Section 7.1. A late payment charge
calculated from the date such payment was due at the [*******] or the highest interest rate allowed by applicable law shall be charged upon all unpaid amounts due hereunder. All payments due hereunder shall be made by wire transfer from a bank in
the United States in immediately available funds to a bank designated by Ovamed, or such other bank upon prior written notice. 
  

	 	7.3	Overdue Amounts; Disputes.  

 Subject to Section 3.2.1, in the event that [*******] disputes in good faith any amount that Ovamed claims to be due under this Agreement [*******] may so notify Ovamed at the time such payment is
made, and if any disputed amount is ultimately determined to not be due hereunder Ovamed will refund promptly [*******] or the highest rate allowable by law at the date of such decision. 
 8. TERM AND TERMINATION. 
  

	 	8.1	Term.  

 Unless
terminated in accordance with Section 8.2, the term (the “Term”) of this Agreement shall commence on the Effective Date and shall continue until the fifth anniversary of the Effective Date, unless earlier terminated pursuant to
the terms of this Agreement, provided that Collingwood may extend the Term for successive one (1) year periods by providing written notice of such extension to Ovamed not later than 12 months prior to the then expiration date of the Term.

  
 - 14 -

	 	8.2	Termination. 

 8.2.1 Termination for Cause. Either Party may terminate this Agreement immediately without penalty or further obligation to the other, upon written notice to the other Party if (i) the
other Party makes a general assignment for the benefit of creditors, or a receiver or similar officer is appointed to take charge of all or substantially all of the other Party’s assets; (ii) the other Party ceases to carry on its
business; (iii) a bankruptcy or similar petition is filed by the other Party or a final insolvency order is issued against the other Party, and in the case of an involuntary petition, the proceeding is not dismissed within 120 days; or
(iv) the other Party is in material breach of any material representation, warranty, covenant or obligation under this Agreement, and such breach is not cured within 60 days of receiving written notice thereof. Without limiting the foregoing,
Collingwood shall have the right to terminate this Agreement as provided in any of Sections 8.2.2 through 8.2.6. The Parties agree that a “material breach of a material obligation” includes but is not limited to any failure by Ovamed to
deliver (x) at least [*******]% of the amount of Product in any particular order pursuant to Section 3.1 within [*******] days of the required delivery date, (y) [*******]% of the amount of Product in any particular order pursuant to
Section 3.1 within [*******] days of the required delivery date or (z) certification reasonably satisfactory to Collingwood pursuant to Section 2.2. 

8.2.2 Failure to Supply. The parties will agree about the quantity to be delivered in forecasts that will be
determined by the parties each year. In the event that Ovamed fails (i) to satisfactorily supply at least [*******]% of the amount of Product in any particular order within [*******] days of the required delivery date or at least [*******]% of
the amount of Product in any particular order within [*******] days of the required delivery date, (ii) to substantially perform its obligations in connection with United States or other relevant Regulatory Approval of the Products and such
failure has continued for more than [*******] days, or such longer period as reasonably necessary to cure such failure or such period required by the relevant Regulatory Approval authority, or (iii) to have adequate operational manufacturing
facilities such that it is unable to manufacture Product, or unable to manufacture product in accordance with Specifications, for a period of [*******] days or more ((i), (ii) and (iii) individually or collectively referred to herein as the
“Manufacturing Failure”), and (x) Ovamed does not, at the time, have the right to terminate this Agreement under Section 8.2.1 and (y) Collingwood has not, at the time, developed a commercial second source (on
commercially reasonable terms) for a product that can be substituted for the Product and that can meet the supply shortage resulting from Ovamed’s failure to supply, then, upon notice of such failure from Collingwood, Collingwood may terminate
this Agreement and receive a worldwide, royalty-free, perpetual, non-transferable (except as set forth in Section 13.3 below), non-exclusive, fully paid license, with the right to grant sublicenses for the sole purpose of manufacturing the
Product on behalf of Collingwood (provided each such sublicensee signs a confidentiality agreement with Ovamed on terms consistent with the confidentiality obligations under this Agreement), under all intellectual property

  
 - 15 -

 
owned by Ovamed or for which Ovamed has the right to grant a license or sublicense pursuant to this Section and which is reasonably necessary or useful to manufacture and sell the Product in the
Field of Use (the “Manufacturing IP”) (collectively, the “Manufacturing Failure License”), and such license shall be effective immediately upon notice of such election by Collingwood, and (b) Ovamed shall provide all
assistance reasonably requested by Collingwood to assist Collingwood or a third party acting on behalf of Collingwood in the manufacturing of the Product in accordance with the Specifications, provided however, that Collingwood shall
reimburse Ovamed for any reasonable expenses it incurs in relation to its rendering of such assistance; Notwithstanding anything to the contrary herein, if Ovamed delivers to Collingwood a remediation plan reasonably acceptable according to which
full remediation of any Manufacturing Failure will be achieved within [*******] months from the first date of such Manufacturing Failure, then this Agreement shall remain in effect, provided however, that Collingwood shall have the right to
use and have used all Manufacturing IP to manufacture or have manufactured Product during such period that Ovamed is engaged in such remediation. Such plan shall be delivered to Collingwood within 30 days after the failure occurred. Collingwood may
terminate this Agreement immediately, without penalty or further obligation to Ovamed, if Ovamed fails to achieve remediation within such [*******] month period and Collingwood shall immediately be entitled to the Manufacturing Failure License.

 8.2.3 Failure to Obtain Regulatory Approval for the Product. Collingwood may terminate this
Agreement immediately, without penalty or further obligation to Ovamed, if Collingwood fails to obtain Regulatory Approval for the Product in the United States, provided that Collingwood will be obligated to: (i) purchase such quantity of
Products that is already scheduled for delivery in the three (3) month period following the date Collingwood notifies Ovamed of such withdrawal requirement (“Withdrawal Notice Date”), and (ii) pay for costs actually
incurred by Ovamed, as of the date of termination pursuant to this Section, in performing the work required under an Collingwood sponsored Change Request. 
 8.2.4 Early Failure in Clinical Trials. Collingwood may terminate this Agreement immediately, without penalty or further obligation to Ovamed, if the Product fails (i) preclinical
pharmacology and toxicology studies or (ii) any clinical trial (or the results from a clinical trial are such that, in Collingwood’s good faith judgment, it would not be commercially reasonable to continue development of the Product)
within 12 months of the Effective Date, provided however, that Collingwood will pay for costs actually incurred by Ovamed, as of the date of termination pursuant to this Section, in performing the work required under an Collingwood sponsored Change
Request. 

  
 - 16 -

 8.2.5 Withdrawal from US or Other Market. In the event FDA or
any other Regulatory Authority requires that the Product be withdrawn from the applicable market, or in the event that Collingwood at any time determines that it is not, or will not be, commercially feasible to market the Product in the United
States or other relevant market, then Collingwood shall have the right, on each such occurrence, to terminate this Agreement immediately, without penalty or further obligation to Ovamed, provided however, that if such withdrawal arises as a result
of a component other than the Product, Collingwood will be obligated to: (i) purchase such quantity of Products that is already scheduled for delivery in the three (3) month period following the date Collingwood notifies Ovamed of such
withdrawal requirement (“Withdrawal Notice Date”), and (ii) pay for costs actually incurred by Ovamed, as of the date of termination pursuant to this Section, in performing the work required under an Collingwood sponsored Change
Request. 
 8.2.6 Termination of Sublicense. This Agreement will terminate immediately upon the
termination of the Sublicense. 
  

	 	8.3	Survival. 

 The Parties
agree that any provisions which by their nature should survive termination or expiration of this Agreement to give effect to their intent, shall survive, including without limitation, Articles 4 (Recalls, Adverse Event Reporting, Complaints), 7
(Payment), 9 (Indemnification and Insurance), 10 (Liability), 11 (Intellectual Property), 12 (Confidential Information), and Sections 8.4 (Survival), 13.1 (Correspondence and Notices), 13.5 (Use of Name), 13.9 (Waiver), 13.10 (Severability), 13.12
(Governing Law), and 13.13 (Jurisdiction; Venue; Service of Process). 
 9. INDEMNIFICATION AND INSURANCE. 

 

	 	9.1	Ovamed Indemnification of Collingwood. 

 Ovamed will defend, indemnify, and hold Collingwood, its officers, directors, employees, and agents (each an “Indemnified Party”) harmless against any and all third party Liabilities to
the extent arising from (i) any asserted infringement or other violation of any third party Intellectual Property Rights arising from Ovamed’s manufacture or supply to Collingwood of the Products under this Agreement; or (ii) any
third party claim arising from personal injury caused by a defect in the manufacture or workmanship of the Product (including claims arising from the Products not meeting the Specifications at the time of delivery). 

 

	 	9.2	Collingwood Indemnification of Ovamed.  

 Collingwood will defend, indemnify, and hold Ovamed, its officers, directors, employees, and agents harmless (each an “Indemnified Party”) against any and all third party Liabilities to the
extent arising from (i) any third party claim against Ovamed asserting infringement or other violation of any third party Intellectual Property Rights arising from the Product (but only to the extent the claim does not arise from the
manufacture, use or sale of the Products); or (ii) any third party claim arising from a personal injury caused by a defect in the Product (but only to the extent the claim does not arise from the Products not meeting the Specifications at the
time of delivery). 

  
 - 17 -

	 	9.3	Procedure.  

 Each
Party will promptly notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought hereunder. In case any proceeding (including any governmental investigation) shall be instituted involving any
Party in respect of which indemnity may be sought pursuant to this Article 9, such Party will promptly notify the other Party (the “Indemnifying Party”) in writing. The Indemnifying Party shall have sole control of any such claim.
The Indemnified Party will reasonably cooperate with the Indemnifying Party in defense of such matter. In any such proceeding, the Indemnified Party will have the right to retain its own counsel, but the fees and expenses of such counsel shall be at
the expense of the Indemnified Party. The Indemnifying Party shall not be liable for any settlement of any proceeding effected without its written consent, but, if settled with such consent or if there be a final judgment for the plaintiff, the
Indemnifying Party agrees to pay any such settlement or final judgment. The Indemnifying Party shall not, without the written consent of the Indemnified Party, effect any settlement of any pending or threatened proceeding in respect of which the
Indemnified Party is, or arising out of the same set of facts could have been, a party and indemnity could have been sought hereunder by the Indemnified Party, unless such settlement includes a release of the Indemnified Party from all liability on
claims that are the subject matter of such proceeding. 
  

	 	9.4	Insurance. 

 Ovamed agrees
to maintain during the Term and for three (3) years thereafter, at its own expense, insurance from a reputable and financially secure insurance company, providing $[*******] of protection per any one occurrence and for the insurance period
against Ovamed’s legal liability deriving from claims, suits, losses and damages arising out of alleged defects in the Products. Collingwood will be named as an additional insured under such policy and Ovamed will provide, at Collingwood’s
request, a certificate of insurance evidencing its obligations hereunder. Such certificate shall provide Collingwood with thirty (30) days written notice of cancellation, modification or termination of such insurance. All such insurance
policies will provide a worldwide coverage territory including suits brought within the United States, its territories and possessions. 
 Collingwood agrees to maintain during the Term and for three (3) years thereafter, at its own expense, insurance from a reputable and financially secure insurance company, providing at least
$[*******] of protection per any one occurrence and for the insurance period against Collingwood’s legal liability deriving from claims, suits, losses and damages arising out of alleged defects in the Product. Ovamed will be named as an
additional insured under such policy and Collingwood will provide, at Ovamed’s request, a certificate of insurance evidencing its obligations hereunder. Such certificate shall provide Ovamed with thirty (30) days written notice of
cancellation, modification or termination of such insurance. All such insurance policies will provide a worldwide coverage territory including suits brought within the United States, its territories and possessions. 

Each Party hereby waives any claims against the other (whether founded upon the indemnification provisions contained in this Agreement or
otherwise) to the extent any such claim is covered by such waiving Party’s insurance carrier, and loss proceeds are paid to and 

  
 - 18 -

 
received by such waiving Party, and provided such waiver (i) is not in violation of the policies of insurance under which such loss proceeds are so paid; (ii) does not invalidate such
insurance and (iii) does not disproportionately increase the premiums thereof. 
 10. LIABILITY. 

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OF ANY KIN) OR NATURE
ARISING OUT OF THIS AGREEMENT, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING THE POSSIBILITY OF NEGLIGENCE OR STRICT LIABILITY), OR OTHERWISE, EVEN IF THE PARTY HAS BEEN WARNED OF THE POSSIBILITY OF ANY SUCH LOSS OR
DAMAGE, AND EVEN IF ANY OF THE LIMITED REMEDIES IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE. 
 11. INTELLECTUAL PROPERTY.

 11.1 Ownership of Intellectual Property. All Intellectual Property Rights developed or conceived by either
party in connection with this Agreement (“Developments”) shall be owned by the party who invented such Development (where inventorship is defined based on concept of inventorship set forth by the patent laws of the United States).
Ovamed has the worldwide, fully paid, perpetual exclusive right to fully exploit such Developments as required to perform its obligations under this Agreement. As long as Collingwood purchases products — fully paid - from Ovamed under this
agreement, Collingwood has the worldwide, fully paid, perpetual license to fully utilize any Developments owned by Ovamed. Collingwood agrees to reasonably cooperate when requested by Ovamed, at Ovamed’s expense, in enforcing Ovamed’s
Intellectual Property Rights embodied in the Developments, including without limitation prosecuting and maintaining patent applications and patents and being joined as a party to an action brought by Ovamed to enforce such rights. Ovamed agrees to
reasonably cooperate when requested by Collingwood, at Collingwood’s expense, in enforcing Collingwood’s Intellectual Property Rights embodied in the Developments, including without limitation prosecuting and maintaining patent
applications and patents and being joined as a party to an action brought by Collingwood to enforce such rights. 
 11.2
Cooperation. Each Party shall promptly notify the other Party of the development or conception of any subject matter arising under and in the performance of this Agreement prior to filing a patent application that discloses such
subject matter. Notwithstanding the foregoing, the Parties acknowledge that the provisions of Article 12 will continue to apply to any proposed disclosure that includes Confidential Information of the other Party. 

11.3 License of Ovamed Intellectual Property Rights. Subject to the terms and conditions of this Agreement, Ovamed hereby
grants to Collingwood and its Affiliates a license under any Ovamed Intellectual Property Rights in order to sell the Product either by Collingwood directly or through third parties. 

  
 - 19 -

 12. CONFIDENTIAL INFORMATION. 

 

	 	12.1	Confidentiality. 

 Except
to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this Agreement and for [*******] years thereafter, each Party (the “Receiving Party”) receiving any
Confidential Information of the other Party (the “Disclosing Party”) hereunder will keep such Confidential Information confidential and will not publish or otherwise disclose or use such Confidential Information for any purpose
other than as provided for in this Agreement, except for Confidential Information that the Receiving Party can establish: 
  

	 	(a)	was already known by the Receiving Party (other than under an obligation of confidentiality) at the time of disclosure by the Disclosing Party and the Receiving Party
has documentary evidence to that effect; 

  

	 	(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

 

	 	(c)	became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, other than through any act or
omission of the Receiving Party or any of its Affiliates; 

  

	 	(d)	was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose
such information to others; or 

  

	 	(e)	was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information belonging to the Disclosing Party and
the Receiving Party has documentary evidence to that effect. 

  

	 	(f)	is necessary to prepare and/or conduct litigation 

  

	 	12.2	Authorized Disclosure. 

Notwithstanding the foregoing provisions of Section 12.1, each Party may disclose Confidential Information belonging to the other
Party (i) to employees or Approved Subcontractors of the disclosing Party to the extent such disclosure is necessary for the disclosing Party to perform its obligations under this Agreement, or (ii) to the extent such disclosure is
necessary, in the reasonable opinion of such Party’s legal counsel, to prosecute or defend litigation or to comply with applicable governmental laws or regulations (including, but not limited to, securities laws and regulations), or
(iii) to the extent such disclosure is necessary for any financing or corporate partnering activity of either parties provided that disclosure will be done under a signed CDA in a form substantially in accordance with the provisions of this

  
 - 20 -

 
clause. In the event a Party deems it necessary to disclose to a third party any Confidential Information belonging to the other Party, pursuant to this Section 12.2, the Disclosing Party
will to the extent possible give reasonable advance notice of such disclosure to the other Party and take reasonable measures to ensure, including without limitation redacting portions of this Agreement prior to disclosure, as reasonably requested
by the other Party, and ensuring that such third party is bound by and complies with the confidentiality terms of this Agreement. 
  

	 	12.3	No Confidential Information of Other Parties. 

 Each Party represents and warrants to the other that it has not used and will not use in the course of its performance hereunder, and will not disclose to the other, any confidential information of any
third party, unless it is expressly authorized in writing by such third party to do so. 
  

	 	12.4	Equitable Relief. 

 Each
Party agrees that the other Party would be irreparably injured by a material breach of the confidentiality and nonuse provisions of this Agreement by the breaching Party or by other parties to whom such Party has disclosed Confidential Information,
that monetary remedies would be inadequate to protect the other Party against any actual or threatened material breach of the provisions of this Article 12 by the breaching Party or by such other authorized third parties, without prejudice to any
other rights and remedies otherwise available to the other Party, the breaching Party agrees, upon proof of any such actual or threatened material breach, to the granting of equitable relief, including injunctive relief and specific performance. It
is further understood and agreed that no failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any other right, power or privilege hereunder. 
 13. MISCELLANEOUS. 

 

	 	13.1	Correspondence and Notices.  

 All notices or other communications to a Party required or permitted hereunder will be in writing and will be delivered personally or by facsimile (receipt confirmed) to such Party (or, in the case of an
entity, to an executive officer of such party) or will be given by certified mail, postage prepaid with return receipt requested, addressed as set forth below in this Section 13.1. Each Party may change its respective above-specified recipient
and/or mailing address by notice to the other Party given in the manner herein prescribed. All notices will be deemed given on the day when actually delivered as provided above (if delivered personally or by facsimile) or on the day shown on the
return receipt (if delivered by mail). 
 All correspondence to Collingwood shall be addressed as follows: 

Collingwood Pharmaceuticals, Inc. 
 787 Seventh Avenue 
 New York, NY 10019 

Attn: Frank Taffy 
 Tel: (212) 554-4385 
 Fax: (212) 554-4355 

  
 - 21 -

 With a copy to: 
 Hemmie Chang, Esq. 
 Ropes & Gray LLP 

One International Place 
 Boston, MA 02110 
 Tel: (617) 951-7317 

Fax: (617) 951-7050 
 All correspondence to Ovamed shall be addressed as follows: 
 Ovamed GmbH

 Kiebitzhörn 33-35 
 22885 Barsbüttel 
 Germany 

Attention: Detlev Goj 
 Tel: +49-40-67 50 95-0 
 With a copy to: 

Klaus Lodigkeit 

c/o Vorberg Rechtsanwälte 
 Rappstraiße 16 
 20146 Hamburg 

Germany 
  

	 	13.2	Compliance with the Laws; Permits and Licenses. 

 Each Party agrees that it will, in fulfilling its obligations under this Agreement, materially comply with all applicable laws including, but not limited to statutes, codes, rules, regulations,
ordinances, judgments and decrees, now or hereafter in effect. Collingwood agrees that it will materially comply with all applicable laws including, but not limited to statutes, codes, rules, regulations, ordinance, judgments and decrees, now or
hereafter in effect related to the development, manufacture and marketing of the Product. Collingwood also represents and warrants that it has all governmental and regulatory licenses and permits necessary to operate its facilities and fulfill its
obligations under this Agreement. Ovamed also represents and warrants that it has all United States and any other governmental and regulatory licenses and permits necessary to operate its facilities and fulfill its obligations under this Agreement.
Failure to comply with this Section 13.2 will be a material breach of the Agreement. 
  

	 	13.3	Assignment. 

 This
Agreement and the rights and duties appertaining hereto may not be assigned by either Party without first obtaining the written consent of the other, which consent shall not be unreasonably withheld. Any such purported assignment, without the
written consent of the other Party, shall be null and of no effect. Notwithstanding the foregoing, Collingwood may assign 

  
 - 22 -

 
this Agreement without the consent of Ovamed (i) to a purchaser, merging or consolidating corporation, or acquirer of substantially all of Collingwood’s assets or business and/or
pursuant to any reorganization qualifying under section 368 of the Internal Revenue Code of 1986 as amended, as may be in effect at such time, or (ii) to an Affiliate. 

 

	 	13.4	Force Majeure. 

 Neither
Party shall be liable to the other for delay or failure in the performance of the obligations on its part contained in this Agreement if and to the extent that such failure or delay is due to circumstances beyond its control that it could not have
avoided by the exercise of reasonable diligence, including without limitation, acts of God or of the public enemy, acts of the government in either its sovereign or contractual capacity, acts of terrorism, fires, floods, war, earthquakes, epidemics,
quarantine restrictions, strikes, freight embargoes, unusually severe weather, the failure of Ovamed’s suppliers or carriers to meet their contractual obligations, or if necessary raw material is unavailable (each a “Force Majeure
Event”). The Party relying on this Section will notify the other Party promptly in the event such circumstances arise, giving an indication of the likely extent and duration thereof, and will use all commercially reasonable efforts to
resume performance of its obligations as soon as practicable; provided, however, that neither Party shall be required to settle any labor dispute or disturbance. During the period that the performance by one of the Parties of
its obligations under this Agreement has been suspended by reason of an event of Force Majeure, the other Party may likewise suspend the performance of all or part of its obligations hereunder to the extent that such suspension is commercially
reasonable. 
  

	 	13.5	Use of Name. 

 Except as
required by law, neither Party will use any trade name, trademark or service mark of the other Party, or of any of the other Party’s Affiliates, in any advertising, promotional or sales literature, offering materials, business plan or any other
form of publicity without the other Party’s prior written consent. 
  

	 	13.6	Language of the Agreement.  

 The language of this Agreement shall be English and the parties hereby waive, and agree that this Agreement shall be valid and enforceable notwithstanding, any requirement that it be written in or
translated into any language other than English. If, for any reason, this Agreement is translated into a language other than English, the English language version shall be controlling for all purposes. 

 

	 	13.7	UN Convention on Contracts for Sale of Goods. 

 The parties expressly agree that the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 

 

	 	13.8	Amendment. 

 No amendment,
modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

  
 - 23 -

 13.9 Waiver. 
 No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a
duly authorized officer of the waiving Party. 
 13.10 Severability. 

If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not
affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this
Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefore such provision as will most nearly carry out the intent of the Parties as expressed in this
Agreement to the fullest extent permitted by applicable law. 
 13.11 Descriptive Headings. 

The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or interpreting any
of the provisions of this Agreement. 
 13.12 Governing Law. 

This Agreement, the rights of the Parties and all claims arising under or in connection herewith, shall be governed by and interpreted in
accordance with the substantive laws of Germany, without regard to conflict of law principles thereof that would cause the application of the laws of any other jurisdiction. 
 13.13 Jurisdiction; Venue; Service of Process. 
 13.13.1.
Jurisdiction. Each Party by its execution hereof, (a) hereby irrevocably submits to the jurisdiction of the courts of Germany for the purpose of any claim, controversy, action, cause of action, suit or litigation (“Action”)
between the parties arising in whole or in part under or in connection with this Agreement, (b) hereby waives to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such
Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such Action brought in one of the above-named courts should be dismissed
on grounds of forum non conveniens, should be transferred or removed to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named
courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court and (c) hereby agrees not to commence any such Action other than before one of the above-named courts. Notwithstanding the previous sentence a
Party may commence any Action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment issued by one of the above-named courts or in connection with injunctive relief. 

  
 - 24 -

 13.13.2 . Venue. Each Party agrees that for any Action between
the parties arising in whole or in part under or in connection with this Agreement, any Action brought shall be brought in Germany. 
 13.14 Entire Agreement.  
 This Agreement and the Exhibits attached
hereto constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between
the Parties respecting the subject matter hereof and thereof. 
 13.15 Conflicts. 

The Parties agree that, to the extent there is an inconsistency between the terms of this Agreement and the terms of the Sublicense, the
terms of the Sublicense shall govern. 
 13.16 Independent Contractors. 

Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency,
joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall
have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

13.17 Counterparts. 
 This Agreement may be executed in any number of counterparts, each of which need not contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same
agreement. 
 [Signature page follows.] 

  
 - 25 -

 IN WITNESS WHEREOF, the parties hereto have as of the Effective Date duly executed
this Agreement, including the attached Exhibits that are incorporated herein and made a part hereof. 
  

			
	COLLINGWOOD PHARMACEUTICALS, INC.

 

			
	      By:	 	 /s/ J. Jay
Lobell

			
	      Name:	 	J. Jay Lobell
	      Title:	 	President
	
	OVAMED GMBH

 

			
	      By:	 	
 

			
	      Name:	 	
	      Title:	 	

  

 Exhibit A 
 Specifications for TSO 
  

			
	Parameters	  	TSO specification
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  

 Vial 
 Name and address of manufacturer: 

             
 Physical description:              
 Size:              
 Closure
System 
 Product name:              

Name and address of manufacturer: 

             
 Physical description:              
 Size:              

 Exhibit B 
 Development and regulatory work to be performed by Ovamed 

 Exhibit C 
 Raw Materials Index 

 Exhibit D 
 TSO US- Specification 
  

			
	Parameters	  	Specification       
         
	 	 
	 	  	 
	 	 
	 	  	 
	 	 
	 	  	 
	 	 
	 	  	 
	 	 
	 	  	 
	 	 
	 	  	 

 Exhibit E 
 Clinical Plan for Product

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]